Détail - canceropole-wordpress

Bevacizumab-based chemotherapy adaptive to pharmacokinetic of bevacizumab in first-line treatment of patients with unresectable metastatic colorectal cancer: A double-blind, multicenter, randomized phase III trial study (PHARBEVACOL trial).

Lecomte T, Giraudeau B, Phelip JM, Tournigand C, Ducreux M, Tougeron D, Lepage C, Mineur L, Laplaige P, Desgrippes R, Artru P, Borg C, Jary M, Bouché O, Metges JP, Guimbaud R, Aparicio T, Foubert F, Hautefeuille V, Muller M, Bouhier-Leporrier K, Darrius R, Lobet S, Monmousseau F, Bejan-Angoulvant T, Paintaud G, Ternant D

Dig Liver Dis. 2025 03 4;:

Clinical description and development of a prognostic score for neurofibromatosis type 1 (NF1)-associated GISTs: a retrospective study from the NETSARC.

Cuvelier C, Brahmi M, Sobhani I, Verret B, Grancher A, Penel N, Toulmonde M, Lahlou W, Dupuis H, Calavas L, Muller M, Watson S, Bruyat D, Poumeaud F, Chaigneau L, Manfredi S, Lecomte T, Bertucci F, Ghiringhelli F, Pracht M, Mourthadhoi F, Monceau-Baroux L, Helyon M, Kurtz JE, Roquin G, Regenet N, Vinches M, Tougeron D, Wolkenstein P, Blay JY, Bouche O, Hautefeuille V

ESMO Open. 2025 03 4;10(3):104477

Impact of low muscle mass and myosteatosis on treatment toxicity and survival outcomes in non-resectable pancreatic cancer patients treated with chemoradiotherapy.

Perrier M, Fontaine M, Bertin E, Carlier C, Botsen D, Djelouah M, François E, Guilbert P, Saint A, Slimano F, Torielli P, Brugel M, Bouché O

Eur J Clin Nutr. 2025 02 5;:

Combined Analyses of Circulating Tumor DNA and Immunoscore in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France/HORG-IDEA-Greece Trials.

Taieb J, Souglakos J, Boukovinas I, Falcoz A, Pages F, Messaritakis I, Bennouna J, Artru P, Louvet C, Lepere C, Emile JF, Bouche O, Mazard T, Vernerey D, Vogiatzoglou K, Tzardi M, Sharma S, Liu MC, Sethi H, André T, Galon J, Laurent-Puig P

J Clin Oncol. 2025 02 4;:JCO2400648

First-line chemotherapy with selective internal radiation therapy for intrahepatic cholangiocarcinoma: The French ACABi GERCOR PRONOBIL cohort.

Adamus N, Edeline J, Henriques J, Fares N, Lecomte T, Turpin A, Vernerey D, Vincens M, Chanez B, Tougeron D, Tournigand C, Assenat E, Delaye M, Manfredi S, Bouché O, Williet N, Vienot A, Blaise L, Mas L, Neuzillet C, Boilève A, Roth GS

JHEP Rep. 2025 02;7(2):101279

The METACER national cohort study of brain metastases in gastrointestinal cancers prospectively establishes prognostic factors.

Randrian V, Portales F, Bouché O, Thezenas S, Chibaudel B, Mabro M, Terrebonne E, Garnier-Tixidre C, Louvet C, André T, Aparicio T, Dubreuil O, Bouché G, Ychou M, Tougeron D

J Neurooncol. 2025 01 2;:

Rectal cancer - French intergroup clinical practice guidelines for diagnosis, treatment, and follow-up (TNCD, SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFP, RENAPE, SNFCP, AFEF, SFR, and GRECCAR).

Cotte E, Arquilliere J, Artru P, Bachet JB, Benhaim L, Bibeau F, Christou N, Conroy T, Doyen J, Hoeffel C, Meillan N, Mirabel X, Pioche M, Rivin Del Campo E, Vendrely V, Huguet F, Bouché O, ,,,,,,,,,,,,,

Dig Liver Dis. 2024 12 17;:

Pesticides and risk of pancreatic adenocarcinoma in France: a nationwide spatiotemporal ecological study between 2011 and 2021.

Brugel M, Gauthier V, Bouché O, Blangiardo M, Génin M

Eur J Epidemiol. 2024 11 25;:

A simple prognostic score to predict recurrence after pancreaticoduodenectomy for ampullary carcinoma: results from the French prospective FFCD-AC cohort.

Roth G, Pellat A, Piessen G, le Malicot K, Schwarz L, Gallois C, Tougeron D, Hautefeuille V, Jary M, Benoist S, Amil M, Desgrippes R, Muller M, Lecomte T, Guillet M, Locher C, Genet C, Manfredi S, Bouché O, Taieb J

ESMO Open. 2024 11 18;9(12):103988

Preliminary guidelines for the detection and management of drug-related problems in cancer patients with type 2 diabetes mellitus: a practical resource for oncology pharmacists.

Gossery C, Clarenne J, Barraud S, Brugel M, Boulin M, Carlier C, Perrier M, Botsen D, Hettler D, Kanagaratnam L, Mongaret C, Bouché O, Slimano F

Support Care Cancer. 2024 11 14;32(12):791

Olaparib as maintenance therapy in non resectable pancreatic adenocarcinoma associated with homologous recombination deficiency profile: A French retrospective multicentric AGEO real-world study.

M'Baloula J, Tougeron D, Boilève A, Jeanbert E, Guimbaud R, Ben Abdelghani M, Durand A, Turpin A, Quesada S, Blanc JF, Artru P, Toullec C, Trouilloud I, Pellat A, Touchefeu Y, Pinot J, Caroli-Bosc FX, Taïeb J, Doat S, Bouché O, Védie AL, de Mestier L, Muller M

Eur J Cancer. 2024 10 1;212:115051

A randomized study of 6 vs 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse.

Blay JY, Schiffler C, Bouché O, Brahmi M, Duffaud F, Toulmonde M, Landi B, Lahlou W, Pannier D, Bompas E, Bertucci F, Chaigneau L, Collard O, Pracht M, Henon C, Ray-Coquard I, Armoun K, Salas S, Spalato-Ceruso M, Adenis A, Verret B, Penel N, Moreau-Bachelard C, Italiano A, Dufresne A, Metzger S, Chabaud S, Perol D, Le Cesne A

Ann Oncol. 2024 09 4;:

Evaluation of serum mid-infrared spectroscopy as new prognostic marker for first-line bevacizumab-based chemotherapy in metastatic colorectal cancer.

Chautard R, Caulet M, Bouché O, Borg C, Manfredi S, Capitain O, Spano JP, Raoul W, Guéguinou M, Herault O, Ferru A, Pobel C, Sire O, Lecomte T

Dig Liver Dis. 2024 08 19;:

Association between pancreatic adenocarcinoma risk and concentration of organochlorine pesticides in adipose tissue and urine: A targeted-screening analysis case-control study (PESTIPAC).

Brugel M, Callon S, Carlier C, Amroun KL, Botsen D, Kianmanesh R, Perrier M, Piardi T, Renard Y, Rhaiem R, El Balkhi S, Bouché O

United European Gastroenterol J. 2024 08 8;:

Incidence of hand-foot syndrome with protein kinase inhibitors in advanced hepatocellular carcinoma patients who received atezolizumab-bevacizumab combination.

Perrier M, Zuccaro E, Carlier C, Brugel M, Slimano F, Bouché O

J Oncol Pharm Pract. 2024 08 1;:10781552241269738

Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial.

Conroy T, Castan F, Etienne PL, Rio E, Mesgouez-Nebout N, Evesque L, Vendrely V, Artignan X, Bouché O, Gargot D, Boige V, Bonichon-Lamichhane N, Louvet C, Morand C, de la Fouchardière C, Boilève A, Delaye M, Gourgou S, Pezzella V, Borg C

Ann Oncol. 2024 07 8;:

Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma.

Fraunhoffer N, Hammel P, Conroy T, Nicolle R, Bachet JB, Harlé A, Rebours V, Turpin A, Abdelghani MB, Mitry E, Biagi J, Chanez B, Bigonnet M, Lopez A, Evesque L, Lecomte T, Assenat E, Bouché O, Renouf D, Lambert A, Monard L, Mauduit M, Cros J, Iovanna J, Dusetti N

Ann Oncol. 2024 06 19;:

How to Balance Prognostic Factors in Controlled Phase II Trials: Stratified Permuted Block Randomization or Minimization? An Analysis of Clinical Trials in Digestive Oncology.

Martin E, Le Malicot K, Guérin-Charbonnel C, Bocquet F, Bouché O, Turpin A, Aparicio T, Legoux JL, Dahan L, Taieb J, Lepage C, Dourthe LM, Pétorin C, Bourgeois V, Raoul JL, Seegers V

Curr Oncol. 2024 06 17;31(6):3513-3528

Prognostic value of the tumor-to-liver density ratio in patients with metastatic colorectal cancer treated with bevacizumab-based chemotherapy. A post-hoc study of the STIC-AVASTIN trial.

Mazard T, Mollevi C, Loyer EM, Léger J, Chautard R, Bouché O, Borg C, Armand-Dujardin P, Bleuzen A, Assenat E, Lecomte T

Cancer Imaging. 2024 06 17;24(1):77

Motor disorders related to oxaliplatin-induced peripheral neuropathy: long-term severity and impact on quality of life.

Balayssac D, Kerckhove N, Selvy M, Pereira B, Gonneau C, Pétorin C, Vimal-Baguet A, Melnikov S, Kullab S, Hebbar M, Bouché O, Slimano F, Bourgeois V, Lebrun-Ly V, Thuillier F, Mazard T, Tavan D, Benmammar KE, Monange B, Ramdani M, Péré-Vergé D, Huet-Penz F, Bedjaoui A, Genty F, Leyronnas C, Pezet D, Martin V

Support Care Cancer. 2024 06 13;32(7):427

Ampullary tumors: French Intergroup Clinical Practice Guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, ACHBT, AFC, SFRO, RENAPE, SNFCP, AFEF, SFP, SFR).

Hautefeuille V, Williet N, Turpin A, Napoleon B, Dupré A, Huguet F, Bignon AL, Camus M, Chevaux JB, Coriat R, Cros J, Edeline J, Koch S, Neuzillet C, Perkins G, Regimbeau JM, Sefrioui D, Vitellius C, Vullierme MP, Bouché O, Gaujoux S, ,,,,,,,,,,,,,

Dig Liver Dis. 2024 06 5;:

Visceral fat and clinical outcome in patients receiving first-line chemotherapy with bevacizumab for metastatic colorectal cancer.

Cazeneuve N, Bouché O, Leger J, Borg C, Labbe-Devilliers C, Lucidarme O, Tasu JP, Manfredi S, Aubé C, Trillaud H, Manzoni P, Marcus C, Terrebonne E, Douillard JY, Chautard R, Lobet S, Scotto B, Bleuzen A, Lecomte T

Clin Res Hepatol Gastroenterol. 2024 05 23;48(7):102380

Trifluridine/tipiracil + oxaliplatin ± nivolumab vs FOLFOX ± nivolumab in HER2 negative advanced oesogastric adenocarcinoma: The PRODIGE73-UCGI40-LOGICAN trial.

Botsen D, Chabaud S, Perrier H, Ammarguellat H, Jestin-Le-Tallec V, Olesinski J, Toullec C, Aparicio T, Ben Abdelghani M, Borg C, Bouche O, Coutzac C, Devaud H, Di Fiore F, Dubreuil O, Evesque L, Huguenin B, Muller M, Poureau PG, Oularue E, Tougeron D, Zaanan A, Ammari S, De Sousa Carvalho N, Decazes P, De La Fouchardiere C

Dig Liver Dis. 2024 05 17;:

Clinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancer.

Boisteau E, Dahan L, Williet N, Le Malicot K, Desramé J, Bouché O, Petorin C, Malka D, Rebischung C, Aparicio T, Lecaille C, Rinaldi Y, Turpin A, Bignon AL, Bachet JB, Lepage C, Granger V, Legoux JL, Deplanque G, Baconnier M, Lecomte T, Bonnet I, Seitz JF, François E, Lièvre A,

Oncologist. 2024 05 4;:

FOLFIRI Plus Durvalumab With or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: The PRODIGE 59-FFCD 1707-DURIGAST Randomized Clinical Trial.

Tougeron D, Dahan L, Evesque L, Le Malicot K, El Hajbi F, Aparicio T, Bouché O, Bonichon Lamichhane N, Chibaudel B, Angelergues A, Bodere A, Phelip JM, Mabro M, Kaluzinski L, Petorin C, Breysacher G, Rinaldi Y, Zaanan A, Smith D, Gouttebel MC, Perret C, Etchepare N, Emile JF, Sanfourche I, Di Fiore F, Lepage C, Artru P, Louvet C,

JAMA Oncol. 2024 04 4;:

Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study.

Kim S, Ghiringhelli F, de la Fouchardière C, Evesque L, Smith D, Badet N, Samalin E, Lopez-Trabada Ataz D, Parzy A, Desramé J, Baba Hamed N, Buecher B, Tougeron D, Bouché O, Dahan L, Chibaudel B, El Hajbi F, Mineur L, Dubreuil O, Ben Abdelghani M, Pecout S, Bibeau F, Herfs M, Garcia ML, Meurisse A, Vernerey D, Taïeb J, Borg C

Lancet Oncol. 2024 04;25(4):518-528

Biliary tract cancers: French national clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACABi, ACHBPT).

Roth GS, Verlingue L, Sarabi M, Blanc JF, Boleslawski E, Boudjema K, Bretagne-Bignon AL, Camus-Duboc M, Coriat R, Créhange G, De Baere T, de la Fouchardière C, Dromain C, Edeline J, Gelli M, Guiu B, Horn S, Laurent-Croise V, Lepage C, Lièvre A, Lopez A, Manfredi S, Meilleroux J, Neuzillet C, Paradis V, Prat F, Ronot M, Rosmorduc O, Cunha AS, Soubrane O, Turpin A, Louvet C, Bouché O, Malka D

Eur J Cancer. 2024 03 13;202:114000

Non-metastatic colon cancer: French Intergroup Clinical Practice Guidelines for diagnosis, treatments, and follow-up (TNCD, SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFP, AFEF, and SFR).

Lecomte T, Tougeron D, Chautard R, Bressand D, Bibeau F, Blanc B, Cohen R, Jacques J, Lagasse JP, Laurent-Puig P, Lepage C, Lucidarme O, Martin-Babau J, Panis Y, Portales F, Taieb J, Aparicio T, Bouché O, ,,,,,,,,,,,

Dig Liver Dis. 2024 02 20;:

Improved nationwide survival of sarcoma patients with a network of reference centers.

Blay JY, Penel N, Valentin T, Anract P, Duffaud F, Dufresne A, Verret B, Cordoba A, Italiano A, Brahmi M, Henon C, Amouyel T, Ray-Coquard I, Ferron G, Boudou-Rouquette P, Tlemsani C, Salas S, Rochwerger R, Faron M, Bompas E, Ducassou A, Gangloff D, Gouin F, Firmin N, Piperno-Neumann S, Rios M, Ropars M, Kurtz JE, Le Nail LR, Bertucci F, Carrere S, Llacer C, Watson S, Bonvalot S, Leroux A, Perrin C, Gantzer J, Pracht M, Narciso B, Monneur A, Lebbe C, Hervieu A, Saada-Bouzid E, Dubray-Longeras P, Fiorenza F, Chaigneau L, Nevieres ZM, Soibinet P, Bouché O, Guillemet C, Spano JP, Ruzic JC, Isambert N, Vaz G, Meeus P, Karanian M, Ngo C, Coindre JM, De Pinieux G, Le Loarer F, Ducimetiere F, Chemin C, Morelle M, Toulmonde M, Le Cesne A

Ann Oncol. 2024 01 19;:

Gemcitabine and Paclitaxel Versus Gemcitabine Alone After 5-Fluorouracil, Oxaliplatin, and Irinotecan in Metastatic Pancreatic Adenocarcinoma: A Randomized Phase III PRODIGE 65-UCGI 36-GEMPAX UNICANCER Study.

De La Fouchardière C, Malka D, Cropet C, Chabaud S, Raimbourg J, Botsen D, Launay S, Evesque L, Vienot A, Perrier H, Jary M, Rinaldi Y, Coutzac C, Bachet JB, Neuzillet C, Williet N, Desgrippes R, Grainville T, Aparicio T, Peytier A, Lecomte T, Roth GS, Thirot-Bidault A, Lachaux N, Bouché O, Ghiringhelli F

J Clin Oncol. 2024 01 17;:JCO2300795

Assessing the time-to-removal of totally implantable venous access devices comparing valved-versus open-ended catheters in patients treated with chemotherapy.

Amroun K, Brugel M, Rhaiem R, Teuma L, Vannieuwenhuyse G, Lipere A, Brenet E, Kianmanesh R, Bouché O

J Vasc Access. 2024 01 11;:11297298231223539

Confounding mitigation for the exposure-response relationship of bevacizumab in colorectal cancer patients.

Lobet S, Caulet M, Paintaud G, Azzopardi N, Desvignes C, Chautard R, Borg C, Capitain O, Ferru A, Bouché O, Lecomte T, Ternant D

Br J Clin Pharmacol. 2023 12 10;:

Effect of Adapted Physical Activity in Patients With Advanced Pancreatic Cancer: The APACaP GERCOR Randomized Trial.

Neuzillet C, Bouché O, Tournigand C, Chibaudel B, Bauguion L, Bengrine-Lefevre L, Lopez-Trabada Ataz D, Mabro M, Metges JP, Péré-Vergé D, Conroy T, Lièvre A, Andre M, Desseigne F, Goldwasser F, Henriques J, Anota A, Hammel P

J Natl Compr Canc Netw. 2023 12;21(12):1234-1242.e17

Adjuvant chemotherapy benefit according to T/N stage in small bowel adenocarcinoma: a large retrospective multicenter study.

Zaanan A, Henriques J, Turpin A, Manfredi S, Coriat R, Terrebonne E, Legoux JL, Walter T, Locher C, Dubreuil O, Pernot S, Vernet C, Bouché O, Hautefeuille V, Gagniere J, Lecomte T, Tougeron D, Grainville T, Vernerey D, Afchain P, Aparicio T

JNCI Cancer Spectr. 2023 09 29;:

Time to recurrence and its relation to survival after recurrence in patients resected for stage III colon cancer.

Rasola C, Laurent-Puig P, André T, Falcoz A, Lepage C, Aparicio T, Bouché O, Lievre A, Mineur L, Bennouna J, Louvet C, Bachet JB, Borg C, Vernerey D, Lonardi S, Taieb J

Eur J Cancer. 2023 09 9;194:113321

Maintenance Therapy With Cetuximab After FOLFIRI Plus Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial.

Boige V, Blons H, François E, Ben Abdelghani M, Phelip JM, Le Brun-Ly V, Mineur L, Galais MP, Villing AL, Hautefeuille V, Miglianico L, De La Fouchardière C, Genet D, Levasseur N, Levaché CB, Penel N, Mitry E, Jacquot S, Aparicio T, Brument E, Gourgou S, Castan F, Bouché O

JAMA Netw Open. 2023 09 5;6(9):e2333533

Esophageal cancer - French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFP, RENAPE, SNFCP, AFEF, SFR).

Veziant J, Bouché O, Aparicio T, Barret M, El Hajbi F, Lepilliez V, Lesueur P, Maingon P, Pannier D, Quero L, Raoul JL, Renaud F, Seitz JF, Serre AA, Vaillant E, Vermersch M, Voron T, Tougeron D, Piessen G, ,,,,,,,,,

Dig Liver Dis. 2023 08 25;:

Avelumab vs Standard Second-Line Chemotherapy in Patients With Metastatic Colorectal Cancer and Microsatellite Instability: A Randomized Clinical Trial.

Taïeb J, Bouche O, André T, Le Malicot K, Laurent-Puig P, Bez J, Toullec C, Borg C, Randrian V, Evesque L, Corbinais S, Perrier H, Buecher B, Di Fiore F, Gallois C, Emile JF, Lepage C, Elhajbi F, Tougeron D,

JAMA Oncol. 2023 08 3;:

Evaluation of the relevance of the growth modulation index (GMI) from the FFCD 0307 randomized phase III trial comparing the sequence of two chemotherapeutic regimens.

du Rusquec P, Guimbaud R, Le Malicot K, Gornet JM, Nguyen S, Lecomte T, Khemissa-Akouz F, Perrier H, Bouché O, Paoletti X, Le Tourneau C

ESMO Open. 2023 08 3;8(4):101616

DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: a multicenter propensity score-matching study.

Kim S, Vendrely V, Saint A, André T, Vaflard P, Samalin E, Pernot S, Bouché O, Zubir M, Desrame J, de la Fouchardière C, Smith D, Ghiringhelli F, Vienot A, Jacquin M, Klajer E, Nguyen T, François É, Taieb J, Le Malicot K, Vernerey D, Meurisse A, Borg C

Exp Hematol Oncol. 2023 07 21;12(1):63

Deep learning for the prediction of the chemotherapy response of metastatic colorectal cancer: comparing and combining H&E staining histopathology and infrared spectral histopathology.

Brunel B, Prada P, Slimano F, Boulagnon-Rombi C, Bouché O, Piot O

Analyst. 2023 07 19;:

Prevalence of cannabidiol (CBD) consumption and cancer patients' expectations in one oncology day-hospital: A cross-sectional study and questionnaire validation.

Le Bozec A, Guédon M, Brugel M, Laurent M, Carlier C, Hettler D, Perrier M, Aubert L, Slimano F, Mongaret C, Bouché O

J Oncol Pharm Pract. 2023 07 12;:10781552231187136

Genetic counselling referral practices for patients with pancreatic adenocarcinoma: A French retrospective multicentre observational cohort study (CAPANCOGEN).

Brugel M, Marulier T, Evrard C, Carlier C, Tougeron D, Piessen G, Truant S, Turpin A, Williet N, Botsen D, Brasseur M, Perrier M, Bouché O

Pancreatology. 2023 06 19;:

Circulating tumour DNA at baseline for individualised prognostication in patients with chemotherapy-naïve metastatic colorectal cancer. An AGEO prospective study.

Bachet JB, Laurent-Puig P, Meurisse A, Bouché O, Mas L, Taly V, Cohen R, Gornet JM, Artru P, Louafi S, Thirot-Bidault A, Baumgaertner I, Coriat R, Tougeron D, Lecomte T, Mary F, Aparicio T, Marthey L, Blons H, Vernerey D, Taieb J

Eur J Cancer. 2023 06 7;189:112934

Beta-blocker exposure and survival outcomes in patients with advanced pancreatic ductal adenocarcinoma: a retrospective cohort study (BETAPANC).

Le Bozec A, Brugel M, Djerada Z, Ayad M, Perrier M, Carlier C, Botsen D, Nazeyrollas P, Bouché O, Slimano F

Front Pharmacol. 2023 05 19;14:1137791

Perioperative Cetuximab with Cisplatin and 5-Fluorouracil in Esogastric Adenocarcinoma: A Phase II Study.

Gronnier C, Mariette C, Lepage C, Monterymard C, Jary M, Ferru A, Baconnier M, Adhoute X, Tavan D, Perrier H, Guerin-Meyer V, Lecaille C, Bonichon-Lamichhane N, Pillon D, Cojocarasu O, Egreteau J, D'journo XB, Dahan L, Locher C, Texereau P, Collet D, Michel P, Ben Abdelghani M, Guimbaud R, Muller M, Bouché O, Piessen G

Cancers (Basel). 2023 04 6;15(7):

Prognostic score for synchronous metastatic rectal cancer: A real-world study.

Muzellec L, Campion L, Bachet JB, Taieb J, Fremont E, Senellart H, Moreau J, Bouché O, Garric M, Guimbaud R, Greilsamer C, Bodère A, Lièvre A, Girot P, Edeline J, Tougeron D, Bennouna J, Touchefeu Y

Dig Liver Dis. 2023 03 31;:

Association of palliative care management and survival after chemotherapy discontinuation in patients with advanced pancreatic adenocarcinoma: A retrospective single-centre observational study.

Brugel M, Dupont M, Carlier C, Botsen D, Essi DE, Sanchez V, Slimano F, Perrier M, Bouché O

Pancreatology. 2023 03 21;:

Cannabidiol-Drug Interaction in Cancer Patients: A retrospective study in a real-life setting.

Guedon M, Le Bozec A, Brugel M, Clarenne J, Carlier C, Perrier M, Laurent M, Hettler D, Mongaret C, Bouché O, Slimano F

Br J Clin Pharmacol. 2023 02 27;:

Carcinoembryonic antigen kinetics predict response to first-line treatment in metastatic colorectal cancer: Analysis from PRODIGE 9 trial.

Salfati D, Huot M, Aparicio T, Lepage C, Taieb J, Bouché O, Boige V, Phelip JM, Dahan L, Bennouna J, Le Malicot K, Boussari O, Gornet JM

Dig Liver Dis. 2023 01 30;:

Renal impairment and abnormal liver function tests in pre-therapeutic phenotype-based DPD deficiency screening using uracilemia: a comprehensive population-based study in 1138 patients.

Callon S, Brugel M, Botsen D, Royer B, Slimano F, Feliu C, Gozalo C, Konecki C, Devie B, Carlier C, Daire V, Laurés N, Perrier M, Djerada Z, Bouché O

Ther Adv Med Oncol. 2023 01 10;15:17588359221148536

Dynamic Prediction of Resectability for Patients with Advanced Ovarian Cancer Undergoing Neo-Adjuvant Chemotherapy: Application of Joint Model for Longitudinal CA-125 Levels.

Amroun K, Chaltiel R, Reyal F, Kianmanesh R, Savoye AM, Perrier M, Djerada Z, Bouché O

Cancers (Basel). 2022 12 30;15(1):

Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trial.

de Rauglaudre B, Sibertin-Blanc C, Fabre A, Le Malicot K, Bennouna J, Ghiringhelli F, Taïeb J, Boige V, Bouché O, Chatellier T, Faroux R, François E, Jacquot S, Genet D, Mulot C, Olschwang S, Seitz JF, Aparicio T, Dahan L

Ther Adv Med Oncol. 2022 12 26;14:17588359221141307

Clinical, Pathological, and Molecular Characteristics in Colorectal Cancer.

Dedieu S, Bouché O

Cancers (Basel). 2022 12 2;14(23):

Incidence and associated factors of cetuximab-induced hypersensitivity infusion reactions in 1392 cancer patients treated in four French areas: a possible association with Lyme disease?

Dupont M, Carlier C, Gower-Rousseau C, Barbier-Lider P, Botsen D, Brasseur M, Burgevin A, Chourbagi C, D'Almeida R, Hautefeuille V, Hentzien M, Lambert A, Lamuraglia M, Lavau-Denes S, Lopez A, Parent D, Slimano F, Brugel M, Bouché O

BMC Cancer. 2022 11 25;22(1):1219

Daily practices in chemotherapy for advanced gastric or gastroesophageal junction adenocarcinoma: METESTOMAC French prospective cohort.

Manfredi S, Dior M, Bouche O, Barbier E, Hautefeuille V, Guillet M, Turpin J, Bourgeois V, Helene DO, Desgrippes R, Audemar F, Molin Y, Locher C, Chatellier T, Lecomte T, Baize N, Lecaille C, Spaeth D, Goujon G, Lepage C, Tougeron D,

Cancer Med. 2022 11 16;:

Postoperative circulating tumor DNA detection is associated with the risk of recurrence in patients resected for a stage II colorectal cancer.

Grancher A, Beaussire L, Manfredi S, Le Malicot K, Dutherage M, Verdier V, Mulot C, Bouché O, Phelip JM, Levaché CB, Deguiral P, Coutant S, Sefrioui D, Emile JF, Laurent-Puig P, Bibeau F, Michel P, Sarafan-Vasseur N, Lepage C, Di Fiore F

Front Oncol. 2022 11 10;12:973167

Neoadjuvant chemotherapy for borderline resectable and upfront resectable pancreatic cancer increasing overall survival and disease-free survival?

Fossaert V, Mimmo A, Rhaiem R, Rached LJ, Brasseur M, Brugel M, Pegoraro F, Sanchez S, Bouché O, Kianmanesh R, Piardi T

Front Oncol. 2022 10 25;12:980659

Association of Low Handgrip Strength with Chemotherapy Toxicity in Digestive Cancer Patients: A Comprehensive Observational Cohort Study (FIGHTDIGOTOX).

Martin P, Botsen D, Brugel M, Bertin E, Carlier C, Mahmoudi R, Slimano F, Perrier M, Bouché O

Nutrients. 2022 10 22;14(21):

Impact of Guidelines Regarding Dihydropyrimidine Dehydrogenase (DPD) Deficiency Screening Using Uracil-Based Phenotyping on the Reduction of Severe Side Effect of 5-Fluorouracil-Based Chemotherapy: A Propension Score Analysis.

Laures N, Konecki C, Brugel M, Giffard AL, Abdelli N, Botsen D, Carlier C, Gozalo C, Feliu C, Slimano F, Djerada Z, Bouché O

Pharmaceutics. 2022 10 6;14(10):

Identification of circulating biomarkers of Crohn's disease and spondyloarthritis using FTIR spectroscopy.

Prada P, Brunel B, Moulin D, Rouillon L, Netter P, Loeuille D, Slimano F, Bouche O, Peyrin-Biroulet L, Jouzeau JY, Piot O

J Biophotonics. 2022 09 16;:e202200200

Preliminary tolerance analysis of adjuvant chemotherapy in older patients after resection of stage III colon cancer from the PRODIGE 34-FFCD randomized trial.

Aparicio T, Bouché O, Etienne PL, Barbier E, Mineur L, Desgrippes R, Guérin-Meyer V, Hocine F, Martin J, Le Brun-Ly V, Cretin J, Desramé J, Rinaldi Y, Cany L, Falandry C, Lefevre LB, Marous M, Terrebonne E, Mosser L, Turpin J, Turpin A, Bauguion L, Reichling C, Van den Eynde M, Carola E, Hiret S

Dig Liver Dis. 2022 09 14;:

Pesticides and pancreatic adenocarcinoma: A transversal epidemiological, environmental and mechanistic narrative review.

Brugel M, Carlier C, Reyes-Castellanos G, Callon S, Carrier A, Bouché O

Dig Liver Dis. 2022 09 8;:

Asymptomatic stenosis of a celiacomesenteric trunk.

Hammoutene C, Durot C, Bouché O, Kianmanesh R, Rhaiem R

Radiol Case Rep. 2022 09;17(9):3090-3093

Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial.

Conroy T, Castan F, Lopez A, Turpin A, Ben Abdelghani M, Wei AC, Mitry E, Biagi JJ, Evesque L, Artru P, Lecomte T, Assenat E, Bauguion L, Ychou M, Bouché O, Monard L, Lambert A, Hammel P,

JAMA Oncol. 2022 09 1;:

Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma.

Kim S, Boustani J, Vernerey D, Vendrely V, Evesque L, Francois E, Quero L, Ghiringhelli F, de la Fouchardière C, Dahan L, Bouché O, Chibaudel B, Hajbi FE, Vernet C, Rebucci-Peixoto M, Feuersinger A, Maritaz C, Borg C

Front Oncol. 2022 08 24;12:918499

Combination of CDX2 H-score quantitative analysis with CD3 AI-guided analysis identifies patients with a good prognosis only in stage III colon cancer.

Derangère V, Lecuelle J, Lepage C, Aoulad-Ben Salem O, Allatessem BM, Ilie A, Bouché O, Phelip JM, Baconnier M, Pezet D, Sebbagh V, Terrebonne E, Bouard G, Jooste V, Bouvier AM, Molimard C, Monnien F, Gonzalez D, Le Malicot K, Rageot D, Truntzer C, Bibeau F, Ghiringhelli F,

Eur J Cancer. 2022 07 1;172:221-230

FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX-bevacizumab failure for COlorectal cancer (BEFLICO): An AGEO multicenter study.

Torregrosa C, Pernot S, Vaflard P, Perret A, Tournigand C, Randrian V, Doat S, Neuzillet C, Moulin V, Stouvenot M, Roth G, Darbas T, Auberger B, Godet T, Jaffrelot M, Lambert A, Dubreuil O, Gluszak C, Bernard-Tessier A, Turpin A, Palmieri LJ, Bouche O, Goujon G, Lecomte T, Sefrioui D, Locher C, Grados L, Gignoux P, Trager S, Nassif E, Saint A, Hammel P, Lecaille C, Bureau M, Perrier M, Botsen D, Bourgeois V, Taieb J, Auclin E

Int J Cancer. 2022 06 15;:

Safety of FOLFIRI + Durvalumab +/- Tremelimumab in Second Line of Patients with Advanced Gastric Cancer: A Safety Run-In from the Randomized Phase II Study DURIGAST PRODIGE 59.

Evrard C, Aparicio T, Soularue E, Le Malicot K, Desramé J, Botsen D, El Hajbi F, Gonzalez D, Lepage C, Bouché O, Tougeron D, On Behalf Of The Durigast-Prodige Investigators/Collaborators

Biomedicines. 2022 05 23;10(5):

One-year COVID-19 outcomes on the oncology care patient pathway: Results of a French descriptive, cross-sectional comprehensive study (ONCOCARE-COV).

Laurent L, Brugel M, Carlier C, Clere F, Bertrand A, Botsen D, Boulagnon-Rombi C, Dalstein V, Debreuve-Theresette A, Deguelte S, Garbar C, Mahmoudi R, Marechal A, Morland D, Rey JB, Schvartz C, Vallet C, Merrouche Y, Slimano F, Bouché O

Cancer Med. 2022 05 20;:

Desmoid tumors located in the abdomen or associated with adenomatous polyposis: French intergroup clinical practice guidelines for diagnosis, treatment, and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFR).

Benech N, Bonvalot S, Dufresne A, Gangi A, Le Péchoux C, Lopez-Trabada-Ataz D, Meurgey A, Nicolas N, Orbach D, Penel N, Salas S, Saurin JC, Walter T, Lecomte T, Bouché O, ,,,,,,,,,

Dig Liver Dis. 2022 May 1;:

Feasibility and Impact of Adapted Physical Activity (APA) in Cancer Outpatients Beginning Medical Anti-Tumoral Treatment: The UMA-CHAPA Study.

Lemoine A, Perrier M, Mazza C, Quinquenel A, Brasseur M, Delmer A, Vallerand H, Dewolf M, Bertin E, Barbe C, Botsen D, Bouché O

Cancers (Basel). 2022 Apr 14;14(8):

PD-1 blockade in solid tumors with defects in polymerase epsilon.

Rousseau B, Bieche I, Pasmant E, Hamzaoui N, Leulliot N, Michon L, de Reynies A, Attignon V, Foote MB, Masliah-Planchon J, Svrcek M, Cohen R, Simmet V, Augereau P, Malka D, Hollebecque A, Pouessel D, Gomez-Roca C, Guimbaud R, Bruyas A, Guillet M, Grob JJ, Duluc M, Cousin S, de la Fouchardiere C, Flechon A, Rolland F, Hiret S, Saada-Bouzid E, Bouche O, Andre T, Pannier D, El Hajbi F, Oudard S, Tournigand C, Soria JC, Champiat S, Gerber DG, Stephens D, Lamendola-Essel MF, Maron SB, Diplas BH, Argiles G, Krishnan AR, Tabone-Eglinger S, Ferrari A, Segal NH, Cercek A, Hoog-Labouret N, Legrand F, Simon C, Lamrani-Ghaouti A, Diaz LA, Saintigny P, Chevret S, Marabelle A

Cancer Discov. 2022 Apr 10;:

Prognosis and chemosensitivity of non-colorectal alimentary tract cancers with microsatellite instability.

Boyer C, Sefrioui D, Cohen R, Chautard R, Perrier M, Lebrun H, Goujon G, Hautefeuille V, Dior M, Walter T, Mary F, Manfredi S, Caroli-Bosc FX, Cervantes B, Coriat R, Deluche E, Zaanan A, Olivier R, Bouché O, Piessen G, Lecomte T, Louvet C, Michel P, Aparicio T, André T, Taieb J, Randrian V, Tougeron D

Dig Liver Dis. 2022 Apr 6;:

Association between proton pump inhibitors and severe hematological toxicity in patients receiving pemetrexed-based anticancer treatment: The prospective IPPEM study.

Slimano F, Le Bozec A, Cransac A, Foucher P, Lesauvage F, Delclaux B, Dory A, Mennecier B, Bertrand B, Gubeno-Dumon MC, Dukic S, Mongaret C, Bouché O, Hettler D, Boulin M, Dewolf M, Kanagaratnam L

Lung Cancer. 2022 Feb 24;166:114-121

Sequential Treatment With Trifluridine/Tipiracil and Regorafenib in Refractory Metastatic Colorectal Cancer Patients: An AGEO Prospective "Real-World Study".

Coutzac C, Trouilloud I, Artru P, Henriques J, Masson T, Doat S, Bouché O, Coriat R, Saint A, Moulin V, Vernerey D, Gallois C, De La Fouchardière C, Tougeron D, Taieb J

Clin Colorectal Cancer. 2022 Feb 14;:

Discoidin Domain Receptor 1 Expression in Colon Cancer: Roles and Prognosis Impact.

Ben Arfi K, Schneider C, Bennasroune A, Bouland N, Wolak-Thierry A, Collin G, Le CC, Toussaint K, Hachet C, Lehrter V, Dedieu S, Bouché O, Morjani H, Boulagnon-Rombi C, Appert-Collin A

Cancers (Basel). 2022 Feb 13;14(4):

Impact of the COVID-19 pandemic on disease stage and treatment for patients with pancreatic adenocarcinoma: A French comprehensive multicentre ambispective observational cohort study (CAPANCOVID).

Brugel M, Letrillart L, Evrard C, Thierry A, Tougeron D, El Amrani M, Piessen G, Truant S, Turpin A, d'Engremont C, Roth G, Hautefeuille V, Regimbeau JM, Williet N, Schwarz L, Di Fiore F, Borg C, Doussot A, Lambert A, Moulin V, Trelohan H, Bolliet M, Topolscki A, Ayav A, Lopez A, Botsen D, Piardi T, Carlier C, Bouché O

Eur J Cancer. 2022 Feb 10;166:8-20

Implications of RAS Mutations on Oncological Outcomes of Surgical Resection and Thermal Ablation Techniques in the Treatment of Colorectal Liver Metastases.

Rhaiem R, Rached L, Tashkandi A, Bouché O, Kianmanesh R

Cancers (Basel). 2022 Feb 5;14(3):

Surveillance of colorectal cancers following curative-intent surgery: "Whatever the cost?"

Lepage C, Bouché O, Phelip JM

Dig Liver Dis. 2022 Jan 10;:

Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial.

Ychou M, Rivoire M, Thezenas S, Guimbaud R, Ghiringhelli F, Mercier-Blas A, Mineur L, Francois E, Khemissa F, Chauvenet M, Kianmanesh R, Fonck M, Houyau P, Aparicio T, Galais MP, Audemar F, Assenat E, Lopez-Crapez E, Jouffroy C, Adenis A, Adam R, Bouché O

Br J Cancer. 2022 Jan 6;:

Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies.

Stouvenot M, Meurisse A, Saint A, Buecher B, André T, Samalin E, Jary M, El Hajbi F, Baba-Hamed N, Pernot S, Kaminsky MC, Bouché O, Desrame J, Zoubir M, Smith D, Ghiringhelli F, Parzy A, de la Fouchardiere C, Almotlak H, Vienot A, Jacquin M, Taieb J, Nguyen T, Vernerey D, Borg C, Kim S

Eur J Cancer. 2022 Jan 4;162:138-147

Time from first seen in specialist care to surgery does not influence survival outcome in patients with upfront resected pancreatic adenocarcinoma.

Brugel M, Bouché O, Kianmanesh R, Teuma L, Tashkandi A, Regimbeau JM, Pessaux P, Royer B, Rhaiem R, Perrenot C, Neuzillet C, Piardi T, Deguelte S

BMC Surg. 2021 Dec 7;21(1):413

Appendiceal tumors and pseudomyxoma peritonei: French Intergroup Clinical Practice Guidelines for diagnosis, treatments and follow-up (RENAPE, RENAPATH, SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFR).

Delhorme JB, Villeneuve L, Bouché O, Averous G, Dohan A, Gornet JM, You B, Bibeau F, Dartigues P, Eveno C, Fontaine J, Kepenekian V, Pocard M, Rousset P, Quenet F, Mariani P, Glehen O, Goéré D

Dig Liver Dis. 2021 Nov 20;:

Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS).

Benhaim L, Bouché O, Normand C, Didelot A, Mulot C, Le Corre D, Garrigou S, Djadi-Prat J, Wang-Renault SF, Perez-Toralla K, Pekin D, Poulet G, Landi B, Taieb J, Selvy M, Emile JF, Lecomte T, Blons H, Chatellier G, Link DR, Taly V, Laurent-Puig P

Eur J Cancer. 2021 Oct 30;159:24-33

Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a Analysis of the PRODIGE-GERCOR IDEA-France Trial.

Taieb J, Taly V, Henriques J, Bourreau C, Mineur L, Bennouna J, Desrame J, Louvet C, Lepere C, Mabro M, Egreteau J, Bouche O, Mulot C, Hormigos K, Chaba K, Mazard T, de Gramont A, Vernerey D, André T, Laurent-Puig P

Clin Cancer Res. 2021 10 15;27(20):5638-5646

Health-Related Quality of Life Analysis in Metastatic Colorectal Cancer Patients Treated by Second-Line Chemotherapy, Associated With Either Cetuximab or Bevacizumab: The PRODIGE 18 Randomized Phase II Study.

Bertaut A, Touchefeu Y, Blanc J, Bouché O, François E, Conroy T, Artru P, Adenis A, Gobbo J, Borg C, Ghiringhelli F, Bennouna J

Clin Colorectal Cancer. 2021 Oct 3;:

Inflammatory biomarkers to predict postoperative infectious complications after cytoreductive surgery and HIPEC for peritoneal carcinomatosis.

Amroun K, Scholer V, Djerada Z, Renard Y, Bouche O, Rhaiem R, Kianmanesh R

Eur J Surg Oncol. 2021 Sep 21;:

Association of COVID-19 Lockdown With the Tumor Burden in Patients With Newly Diagnosed Metastatic Colorectal Cancer.

Thierry AR, Pastor B, Pisareva E, Ghiringhelli F, Bouché O, De La Fouchardière C, Vanbockstael J, Smith D, François E, Dos Santos M, Botsen D, Ellis S, Fonck M, André T, Guardiola E, Khemissa F, Linot B, Martin-Babau J, Rinaldi Y, Assenat E, Clavel L, Dominguez S, Gavoille C, Sefrioui D, Pezzella V, Mollevi C, Ychou M, Mazard T

JAMA Netw Open. 2021 Sep 1;4(9):e2124483

Metastatic colorectal carcinoma with signet-ring cells: Clinical, histological and molecular description from an Association des Gastro-Entérologues Oncologues (AGEO) French multicenter retrospective cohort.

Allart M, Leroy F, Kim S, Sefrioui D, Nayeri M, Zaanan A, Rousseau B, Ben Abdelghani M, de la Fouchardière C, Cacheux W, Legros R, Louafi S, Tougeron D, Bouché O, Fares N, Roquin G, Bignon AL, Maillet M, Pozet A, Hautefeuille V,

Dig Liver Dis. 2021 Aug 9;:

Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial.

Dahan L, Williet N, Le Malicot K, Phelip JM, Desrame J, Bouché O, Petorin C, Malka D, Rebischung C, Aparicio T, Lecaille C, Rinaldi Y, Turpin A, Bignon AL, Bachet JB, Seitz JF, Lepage C, François E,

J Clin Oncol. 2021 Jul 21;:JCO2003329

Dynapenia in digestive cancer outpatients: association with markers of functional and nutritional status (the FIGHTDIGO study).

Perrier M, Ordan MA, Barbe C, Mazza C, Botsen D, Moreau J, Renard Y, Brasseur M, Tailliere B, Regnault P, Bertin E, Bouche O

Support Care Cancer. 2021 Jul 12;:

A case of palmar hypopigmentation induced by capecitabine in a gastrointestinal cancer patient.

Gratiaux J, Gossery C, Rezzag-Mahcene C, Botsen D, Visseaux L, Slimano F, Bouche O

J Oncol Pharm Pract. 2021 Jul 7;:10781552211027936

Starting Imatinib at 400 mg Daily in Patients with Gastrointestinal Stromal Tumors Harboring KIT Exon 9 Mutations: A Retrospective, Multicenter Study.

Callejo A, Faouzi S, Bouché O, Bertucci F, Chevalier T, Isambert N, Duffaud F, Collard O, Penel N, Terrier P, Mir O, Blay JY, Le Cesne A

Target Oncol. 2021 07;16(4):485-492

Locoregional relapses in the accord12/0405-prodige 02 study: dosimetric study and risk factors.

Meillan N, Orthuon A, Chauchat P, Atlani D, Bouche O, Chaulin B, David C, Deberne M, Debrigode C, Kao W, Keller A, Laharie H, Lamezec B, Lemanski C, Magné N, Mahé MA, Mere P, Moureau-Zabotto L, Peiffert D, Pointreau Y, Quéro L, Racadot S, Roca S, Sargos P, Servagi S, Vendrely V, ElianeTang,Doyen J, Huguet F

Radiother Oncol. 2021 Jun 15;:

Predictive factors of severe early treatment-related toxicity in patients receiving first-line treatment for metastatic colorectal cancer: Pooled analysis of 2190 patients enrolled in Fédération Francophone de Cancérologie Digestive (FFCD) trials.

Breton C, Aparicio T, Le Malicot K, Ducreux M, Lecomte T, Bachet JB, Taieb J, Legoux JL, De Gramont A, Benouna J, Bouché O, Boussari O, Manfredi S, Gornet JM

Eur J Cancer. 2021 Jun 12;153:40-50

Impact of follow-up on generalized pairwise comparisons for estimating the irinotecan benefit in advanced/metastatic gastric cancer.

Chamseddine AN, Oba K, Buyse M, Boku N, Bouché O, Satar T, Auperin A, Paoletti X

Contemp Clin Trials. 2021 Apr 15;:106400

Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.

Conroy T, Bosset JF, Etienne PL, Rio E, François É, Mesgouez-Nebout N, Vendrely V, Artignan X, Bouché O, Gargot D, Boige V, Bonichon-Lamichhane N, Louvet C, Morand C, de la Fouchardière C, Lamfichekh N, Juzyna B, Jouffroy-Zeller C, Rullier E, Marchal F, Gourgou S, Castan F, Borg C,

Lancet Oncol. 2021 Apr 13;:

[Vaccination against COVID-19 in patients with solid cancer: Review and point of view from a French oncology inter-group (CGO, TNCD, UNICANCER)].

Tougeron D, Seitz-Polski B, Hentzien M, Bani-Sadr F, Bourhis J, Ducreux M, Gaujoux S, Gorphe P, Guiu B, Hardy-Bessard AC, Hoang Xuan K, Huguet F, Lecomte T, Lièvre A, Louvet C, Maggiori L, Mariani P, Michel P, Servettaz A, Thariat J, Westeel V, Aparicio T, Blay JY, Bouché O, ,,,,,,,,,,,,,

Bull Cancer. 2021 Apr 12;:

Severe acute respiratory syndrome coronavirus 2 vaccination for patients with solid cancer: Review and point of view of a French oncology intergroup (GCO, TNCD, UNICANCER).

Tougeron D, Hentzien M, Seitz-Polski B, Bani-Sadr F, Bourhis J, Ducreux M, Gaujoux S, Gorphe P, Guiu B, Hoang-Xuan K, Huguet F, Lecomte T, Lièvre A, Louvet C, Maggiori L, Mansi L, Mariani P, Michel P, Servettaz A, Thariat J, Westeel V, Aparicio T, Blay JY, Bouché O, ,,,,,,,,,,,,,,,

Eur J Cancer. 2021 Apr 1;150:232-239

Hepatocellular carcinoma: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, AFEF, SIAD, SFR/FRI).

Blanc JF, Debaillon-Vesque A, Roth G, Barbare JC, Baumann AS, Boige V, Boudjema K, Bouattour M, Crehange G, Dauvois B, Decaens T, Dewaele F, Farges O, Guiu B, Hollebecque A, Merle P, Selves J, Aparicio T, Ruiz I, Bouché O, ,,,,,,,,

Clin Res Hepatol Gastroenterol. 2021 Mar 26;45(2):101590

Automatic Identification of Paraffin Pixels on FTIR Images Acquired on FFPE Human Samples.

Boutegrabet W, Guenot D, Bouché O, Boulagnon-Rombi C, Marchal Bressenot A, Piot O, Gobinet C

Anal Chem. 2021 Feb 16;:

Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high-risk stage II and III colon cancers? Three years' follow-up results of the PRODIGE 22 phase II randomized multicenter trial.

Karoui M, Gallois C, Piessen G, Legoux JL, Barbier E, De Chaisemartin C, Lecaille C, Bouche O, Ammarguellat H, Brunetti F, Prudhomme M, Regimbeau JM, Glehen O, Lievre A, Portier G, Hartwig J, Goujon G, Romain B, Lepage C, Taieb J,

Colorectal Dis. 2021 Feb 13;:

Colorectal Cancer Survivors Suffering From Sensory Chemotherapy-Induced Peripheral Neuropathy Are Not a Homogenous Group: Secondary Analysis of Patients' Profiles With Oxaliplatin-Induced Peripheral Neuropathy.

Kerckhove N, Selvy M, Lambert C, Gonneau C, Feydel G, Pétorin C, Vimal-Baguet A, Melnikov S, Kullab S, Hebbar M, Bouché O, Slimano F, Bourgeois V, Lebrun-Ly V, Thuillier F, Mazard T, Tavan D, Benmammar KE, Monange B, Ramdani M, Péré-Vergé D, Huet-Penz F, Bedjaoui A, Genty F, Leyronnas C, Busserolles J, Trévis S, Pinon V, Pezet D, Balayssac D

Front Pharmacol. 2021 ;12:744085

Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODIGE 54 randomised phase II trial.

Taïeb J, André T, El Hajbi F, Barbier E, Toullec C, Kim S, Bouche O, Di Fiore F, Chauvenet M, Perrier H, Evesque L, Laurent-Puig P, Emile JF, Bez J, Lepage C, Tougeron D

Dig Liver Dis. 2020 Dec 24;:

PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer.

Evrard C, Louvet C, Hajbi FE, Fiore FD, Malicot KL, Aparicio T, Bouché O, Laurent-Puig P, Bibeau F, Lecomte T, Lièvre A, Guimbaud R, Kim S, Zaanan A, Sokol H, Chibaudel B, Desrame J, Pierre S, Gonzalez D, Lepage C, Tougeron D

Dig Liver Dis. 2020 Dec 21;:

Management of digestive cancers during the COVID-19 second wave: A French intergroup point of view (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFR).

Tougeron D, Michel P, Lièvre A, Ducreux M, Gaujoux S, Guiu B, Huguet F, Lecomte T, Lepage C, Louvet C, Maggiori L, Mariani P, Aparicio T, Bouché O, ,,,,,,,,,

Dig Liver Dis. 2020 Dec 16;:

Nutrition and physical activity: French intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC, SFP-APA, SFNCM, AFSOS).

Neuzillet C, Anota A, Foucaut AM, Védie AL, Antoun S, Barnoud D, Bouleuc C, Chorin F, Cottet V, Fontaine E, Garabige V, Hébuterne X, Huguet F, Lièvre A, Marchal T, Mouillot T, Peschaud F, Quilliot D, Raynard B, Schneider S, Scotté F, Vansteene D, Mariani P, Bouché O, Joly F, ,,,,,,,,,,,

BMJ Support Palliat Care. 2020 Nov 11;:

Dramatic changes in oncology care pathways during the COVID-19 pandemic: The French ONCOCARE-COV study.

Brugel M, Carlier C, Essner C, Debreuve-Theresette A, Beck MF, Merrouche Y, Bouché O

Oncologist. 2020 Oct 28;:

Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19).

Lièvre A, Turpin A, Ray-Coquard I, Le Malicot K, Thariat J, Ahle G, Neuzillet C, Paoletti X, Bouché O, Aldabbagh K, Michel P, Debieuvre D, Canellas A, Wislez M, Laurent L, Mabro M, Colle R, Hardy-Bessard AC, Mansi L, Colomba E, Bourhis J, Gorphe P, Pointreau Y, Idbaih A, Ursu R, Di Stefano AL, Zalcman G, Aparicio T,

Eur J Cancer. 2020 Oct 8;141:62-81

Long-Term Prevalence of Sensory Chemotherapy-Induced Peripheral Neuropathy for 5 Years after Adjuvant FOLFOX Chemotherapy to Treat Colorectal Cancer: A Multicenter Cross-Sectional Study.

Selvy M, Pereira B, Kerckhove N, Gonneau C, Feydel G, Pétorin C, Vimal-Baguet A, Melnikov S, Kullab S, Hebbar M, Bouché O, Slimano F, Bourgeois V, Lebrun-Ly V, Thuillier F, Mazard T, Tavan D, Benmammar KE, Monange B, Ramdani M, Péré-Vergé D, Huet-Penz F, Bedjaoui A, Genty F, Leyronnas C, Busserolles J, Trevis S, Pinon V, Pezet D, Balayssac D

J Clin Med. 2020 Jul 27;9(8):

Expression of the Serrated Markers Annexin A10 or Gremlin1 in Colonic Adenocarcinomas: Morphology and Prognostic Values.

Marquet B, Marchal Bressenot A, Fichel C, Bouland N, Barbe C, Bouché O, Kianmanesh R, Diebold MD, Boulagnon-Rombi C

Pathol. Oncol. Res.. 2020 Jun 24;:

Sarcopenia: An important prognostic factor for males treated for a locally advanced esophageal carcinoma.

Benadon B, Servagi-Vernat S, Quero L, Cattan P, Guillerm S, Hennequin V, Aparicio T, Lourenço N, Bouché O, Hennequin C

Dig Liver Dis. 2020 May 31;:

Sorafenib Plus Irinotecan Combination in Patients With RAS-mutated Metastatic Colorectal Cancer Refractory To Standard Combined Chemotherapies: A Multicenter, Randomized Phase 2 Trial (NEXIRI-2/PRODIGE 27).

Samalin E, Fouchardière C, Thézenas S, Boige V, Senellart H, Guimbaud R, Taïeb J, François E, Galais MP, Lièvre A, Seitz JF, Metges JP, Bouché O, Boissière-Michot F, Lopez-Crapez E, Bibeau F, Ho-Pun-Cheung A, Ychou M, Adenis A, Di Fiore F, Mazard T

Clin Colorectal Cancer. 2020 May 15;:

COVID-19 epidemic: Proposed alternatives in the management of digestive cancers: A French intergroup clinical point of view (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR).

Di Fiore F, Bouché O, Lepage C, Sefrioui D, Gangloff A, Schwarz L, Tuech JJ, Aparicio T, Lecomte T, Boulagnon-Rombi C, Lièvre A, Manfredi S, Phelip JM, Michel P, ,,,,,,,,

Dig Liver Dis. 2020 May 14;:

Time intervals to diagnosis and chemotherapy do not influence survival outcome in patients with advanced pancreatic adenocarcinoma.

Laurent-Badr Q, Barbe C, Brugel M, Hautefeuille V, Volet J, Grelet S, Desot E, Botsen D, Deguelte S, Pitta A, Abdelli N, Brasseur M, De Mestier L, Neuzillet C, Bouché O

Dig Liver Dis. 2020 Apr 30;:

Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial.

Kim S, Buecher B, André T, Jary M, Bidard FC, Ghiringhelli F, François É, Taieb J, Smith D, de la Fouchardière C, Desramé J, Samalin E, Parzy A, Baba-Hamed N, Bouché O, Tougeron D, Dahan L, El Hajbi F, Jacquin M, Rebucci-Peixoto M, Spehner L, Vendrely V, Vernerey D, Borg C

BMC Cancer. 2020 Apr 25;20(1):352

Treatment of primary and metastatic peritoneal tumors in the Covid-19 pandemic. Proposals for prioritization from the RENAPE and BIG-RENAPE groups.

Glehen O, Kepenekian V, Bouché O, Gladieff L, Honore C,

J Visc Surg. 2020 Apr 23;:

[Treatment of primary and metastatic peritoneal tumors in the Covid-19 pandemic Proposals for prioritization from the RENAPE and BIG-RENAPE groups].

Glehen O, Kepenekian V, Bouché O, Gladieff L, Honore C, Big-Renape R

. 2020 Apr 23;:

Molecular description of ANGPT2 associated colorectal carcinoma.

Jary M, Hasanova R, Vienot A, Asgarov K, Loyon R, Tirole C, Bouard A, Orillard E, Klajer E, Kim S, Viot J, Colle E, Adotevi O, Bouché O, Lecomte T, Borg C, Feugeas JP

Int. J. Cancer. 2020 Mar 29;:

Digestive Neuroendocrine Neoplasms (NEN): French Intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, GTE, RENATEN, TENPATH, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR).

de Mestier L, Lepage C, Baudin E, Coriat R, Courbon F, Couvelard A, Do Cao C, Frampas E, Gaujoux S, Gincul R, Goudet P, Lombard-Bohas C, Poncet G, Smith D, Ruszniewski P, Lecomte T, Bouché O, Walter T, Cadiot G,

Dig Liver Dis. 2020 Mar 28;:

Concurrent losses of skeletal muscle mass, adipose tissue and bone mineral density during bevacizumab / cytotoxic chemotherapy treatment for metastatic colorectal cancer.

Dolly A, Lecomte T, Bouché O, Borg C, Terrebonne E, Douillard JY, Chautard R, Raoul W, Ternant D, Leger J, Bleuzen A, Dumas JF, Servais S, Baracos VE

Clin Nutr. 2020 Feb 22;:

Fully laparoscopic thermo-ablation of liver malignancies with or without liver resection: tumor location is an independent local recurrence risk factor.

Ledoux G, Amroun K, Rhaiem R, Cagniet A, Aghaei A, Bouche O, Hoeffel C, Sommacale D, Piardi T, Kianmanesh R

Surg Endosc. 2020 Feb 19;:

Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial.

Aparicio T, Bennouna J, Le Malicot K, Boige V, Taieb J, Bouché O, Phelip JM, François E, Borel C, Faroux R, Dahan L, Bachet JB, Egreteau J, Kaminsky MC, Gornet JM, Cojocarasu O, Gasmi M, Guerin-Meyer V, Lepage C, Ghiringhelli F,

Br. J. Cancer. 2020 Feb 4;:

Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild-Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study).

Palmieri LJ, Mineur L, Tougeron D, Rousseau B, Granger V, Gornet JM, Smith D, Lievre A, Galais MP, Doat S, Pernot S, Bignon-Bretagne AL, Metges JP, Baba-Hamed N, Michel P, Obled S, Vitellius C, Bouche O, Saban-Roche L, Buecher B, des Guetz G, Locher C, Trouilloud I, Goujon G, Dior M, Manfredi S, Soularue E, Phelip JM, Henriques J, Vernery D, Coriat R

Oncologist. 2020 Feb;25(2):e266-e275

Microwave Thermoablation of Colorectal Liver Metastases Close to Large Hepatic Vessels Under Pringle Maneuver Minimizes the "Heat Sink Effect".

Rhaiem R, Kianmanesh R, Minon M, Tashkandi A, Aghaei A, Ledoux G, Hoeffel C, Bouche O, Sommacale D, Piardi T

World J Surg. 2020 Jan 21;:

Small bowel adenocarcinoma: results from a nationwide prospective ARCAD-NADEGE cohort study of 347 patients.

Aparicio T, Henriques J, Manfredi S, Tougeron D, Bouché O, Pezet D, Piessen G, Coriat R, Zaanan A, Legoux JL, Terrebone E, Pocard M, Gornet JM, Lecomte T, Lombard-Bohas C, Perrier H, Lecaille C, Lavau-Denes S, Vernerey D, Afchain P,

Int. J. Cancer. 2020 Jan 7;:

Pooled analysis of 115 patients from updated data of Epitopes-HPV01 and Epitopes-HPV02 studies in first-line advanced anal squamous cell carcinoma.

Kim S, Meurisse A, Spehner L, Stouvenot M, François E, Buecher B, André T, Samalin E, Jary M, Nguyen T, El Hajbi F, Baba-Hamed N, Pernot S, Kaminsky MC, Bouché O, Desrame J, Zoubir M, Ghiringhelli F, Parzy A, de la Fouchardiere C, Boulbair F, Lakkis Z, Klajer E, Jacquin M, Taieb J, Vendrely V, Vernerey D, Borg C

Ther Adv Med Oncol. 2020 ;12:1758835920975356

Multicenter phase III randomized trial comparing laparoscopy and laparotomy for colon cancer surgery in patients older than 75 years: the CELL study, a Fédération de Recherche en Chirurgie (FRENCH) trial.

Manceau G, Brouquet A, Chaibi P, Passot G, Bouché O, Mathonnet M, Regimbeau JM, Lo Dico R, Lefèvre JH, Peschaud F, Facy O, Volpin E, Chouillard E, Beyert-Berjot L, Verny M, Karoui M, Benoist S

BMC Cancer. 2019 Dec 4;19(1):1185

Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial.

Hammel P, Fabienne P, Mineur L, Metges JP, Andre T, De La Fouchardiere C, Louvet C, El Hajbi F, Faroux R, Guimbaud R, Tougeron D, Bouche O, Lecomte T, Rebischung C, Tournigand C, Cros J, Kay R, Hamm A, Gupta A, Bachet JB, El Hariry I

Eur. J. Cancer. 2019 Nov 21;124:91-101

Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in Wild-Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study).

Palmieri LJ, Mineur L, Tougeron D, Rousseau B, Granger V, Gornet JM, Smith D, Lievre A, Galais MP, Doat S, Pernot S, Bignon-Bretagne AL, Metges JP, Baba-Hamed N, Michel P, Obled S, Vitellius C, Bouche O, Saban-Roche L, Buecher B, des Guetz G, Locher C, Trouilloud I, Goujon G, Dior M, Manfredi S, Soularue E, Phelip JM, Henriques J, Vernery D, Coriat R

Oncologist. 2019 Oct 2;:

Management of skin toxicities during panitumumab treatment in metastatic colorectal cancer.

Bouché O, Ben Abdelghani M, Labourey JL, Triby S, Bensadoun RJ, Jouary T, Des Guetz G

World J. Gastroenterol.. 2019 Aug 7;25(29):4007-4018

Gastrointestinal stromal tumours (GISTs): French Intergroup Clinical Practice Guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO).

Landi B, Blay JY, Bonvalot S, Brasseur M, Coindre JM, Emile JF, Hautefeuille V, Honore C, Lartigau E, Mantion G, Pracht M, Le Cesne A, Ducreux M, Bouche O,

Dig Liver Dis. 2019 Aug 3;:

Mutation Status in Circulating Tumor DNA from Patients with Metastatic Colorectal Cancer: Extended Mutation Analysis from the AGEO RASANC Study.

Mas L, Bachet JB, Taly V, Bouché O, Taieb J, Cohen R, Meurisse A, Normand C, Gornet JM, Artru P, Louafi S, Thirot-Bidault A, Baumgaertner I, Coriat R, Tougeron D, Lecomte T, Mary F, Aparicio T, Marthey L, Blons H, Vernerey D, Laurent-Puig P

Cancers (Basel). 2019 Jul 17;11(7):

Metastatic colorectal cancer (mCRC): French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR).

Phelip JM, Tougeron D, Léonard D, Benhaim L, Desolneux G, Dupré A, Michel P, Penna C, Tournigand C, Louvet C, Christou N, Chevallier P, Dohan A, Rousseaux B, Bouché O

Dig Liver Dis. 2019 Jul 15;:

Perioperative FOLFOX 4 Versus FOLFOX 4 Plus Cetuximab Versus Immediate Surgery for High-Risk Stage II and III Colon Cancers: A Phase II Multicenter Randomized Controlled Trial (PRODIGE 22).

Karoui M, Rullier A, Piessen G, Legoux JL, Barbier E, De Chaisemartin C, Lecaille C, Bouche O, Ammarguellat H, Brunetti F, Prudhomme M, Regimbeau JM, Glehen O, Lievre A, Portier G, Hartwig J, Goujon G, Romain B, Lepage C, Taieb J,

Ann. Surg.. 2019 Jul 6;:

Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance.

Pernot S, Terme M, Radosevic-Robin N, Castan F, Badoual C, Marcheteau E, Penault-Llorca F, Bouche O, Bennouna J, Francois E, Ghiringhelli F, De La Fouchardiere C, Samalin E, Baptiste Bachet J, Borg C, Boige V, Voron T, Stanbury T, Tartour E, Gourgou S, Malka D, Taieb J

Gastric Cancer. 2019 Jul 2;:

Regorafenib combined with irinotecan as second-line treatment in patients with metastatic gastro-oesophageal adenocarcinomas: A randomized phase 2 trial (PRODIGE 58 - UCGI 35 - REGIRI).

Samalin E, Turpin A, Khemissa F, Zaanan A, Benabdelghani M, Senellart H, Gilabert M, Evesque L, Dahan L, Sefrioui D, Bouché O, De la Fouchardière C, Hennequin A, Monard L, Gourgou S, Lopez A

Ann. Oncol.. 2019 Jul;30 Suppl 4:iv21

[Dihydropyrimidine dehydrogenase deficiency screening for management of patients receiving a fluoropyrimidine: Results of two national practice surveys addressed to clinicians and biologists].

Loriot MA, Masskouri F, Carni P, Le Malicot K, Seitz JF, Michel P, Legoux JL, Bouché O, André T, Faroux R, Delaloge S, Malka D, Guigay J, Thariat J, Thomas F, Barin-Le-Guellec C, Ciccolini J, Boyer JC, Étienne-Grimaldi MC

Bull Cancer. 2019 Jun 25;:

Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodige-14 Trial.

Bidard FC, Kiavue N, Ychou M, Cabel L, Stern MH, Madic J, Saliou A, Rampanou A, Decraene C, Bouché O, Rivoire M, Ghiringhelli F, Francois E, Guimbaud R, Mineur L, Khemissa-Akouz F, Mazard T, Moussata D, Proudhon C, Pierga JY, Stanbury T, Thézenas S, Mariani P

Cells. 2019 May 28;8(6):

FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial.

Malka D, François E, Penault-Llorca F, Castan F, Bouché O, Bennouna J, Ghiringhelli F, Fouchardière C, Borg C, Samalin E, Bachet JB, Raoul JL, Miglianico L, Bengrine-Lefèvre L, Dahan L, Lecaille C, Aparicio T, Stanbury T, Perrier H, Cayre A, Laurent-Puig P, Gourgou S, Emile JF, Taïeb J

Eur. J. Cancer. 2019 May 23;115:97-106

Correlation between muscle mass and handgrip strength in digestive cancer patients undergoing chemotherapy.

Moreau J, Ordan MA, Barbe C, Mazza C, Perrier M, Botsen D, Brasseur M, Portefaix C, Renard Y, Tallière B, Bertin E, Hoeffel C, Bouché O

Cancer Med. 2019 May 21;:

Pravastatin combination with Sorafenib does not improve survival in advanced Hepatocellular Carcinoma.

Jouve JL, Lecomte T, Bouché O, Barbier E, Akouz FK, Riachi G, Khac EN, Ollivier-Hourmand I, Debette-Gratien M, Faroux R, Villing AL, Vergniol J, Ramee JF, Bronowicki JP, Seitz JF, Legoux JL, Denis J, Manfredi S, Phelip JM,

J. Hepatol.. 2019 May 21;:

Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.

Dohan A, Gallix B, Guiu B, Le Malicot K, Reinhold C, Soyer P, Bennouna J, Ghiringhelli F, Barbier E, Boige V, Taieb J, Bouché O, François E, Phelip JM, Borel C, Faroux R, Seitz JF, Jacquot S, Ben Abdelghani M, Khemissa-Akouz F, Genet D, Jouve JL, Rinaldi Y, Desseigne F, Texereau P, Suc E, Lepage C, Aparico T, Hoeffel C,

Gut. 2019 May 17;:

Oxaliplatin-desensitization procedure is safe and feasible in an outpatient cancer unit in France.

Botsen D, Lepoix E, Mazza C, Brasseur M, Grange A, Slimano F, Bouché O

Support Care Cancer. 2019 May 17;:

Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase 2 study.

Toulmonde M, Bellera CA, Blay JY, Bouche O, Mir O, Penel N, Isambert N, Duffaud F, Esnaud T, Boidot R, Geneste D, Ghiringhelli F, Lucchesi C, Le Loarer F, Italiano A

Clin. Cancer Res.. 2019 Apr 12;:

Sorafenib alone vs. sorafenib plus GEMOX as 1-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial.

Assenat E, Pageaux GP, Thézenas S, Peron JM, Bécouarn Y, Seitz JF, Merle P, Blanc JF, Bouché O, Ramdani M, Poujol S, de Forges H, Ychou M, Boige V

Br. J. Cancer. 2019 Apr 4;:

Sarcomas in patients over 90: natural history and treatment. A nationwide study over 6 years.

Basse C, Italiano A, Penel N, Mir O, Chemin C, Toulmonde M, Duffaud F, Le Cesne A, Chevreau C, Maynou C, Anract P, Gouin F, Rios M, Firmin N, Kurtz JE, Kerbrat P, Piperno-Neumann S, Bertucci F, Rosset P, Isambert N, Bompas E, Dubray-Longeras P, Fiorenza F, Le Maignan C, Chaigneau L, Thyss A, Bouché O, Eymard JC, Lair CD, Adam J, Karanian M, Lebbé C, Dupré A, Meeus P, Brahmi M, Dufresne A, Ducimetière F, Ray-Coquard I, Blay JY

Int. J. Cancer. 2019 Mar 28;:

Quality of life and cost of strategies of two chemotherapy lines in metastatic colorectal cancer: results of the FFCD 2000-05 trial.

Lacas B, Bouché O, Etienne PL, Gasmi M, Texereau P, Gargot D, Lombard-Bohas C, Azzedine A, Denis B, Geoffroy P, Auby D, Michel P, Pignon JP, Lepage C, Ducreux M, Borget I

Expert Rev Pharmacoecon Outcomes Res. 2019 Feb 9;:

Nightmares and hallucinations with aprepitant and opium powder: a suspected drug-drug interaction.

Narjoux G, Clarenne J, Azzouz B, Zeller PS, Slimano F, Bouché O

Br J Clin Pharmacol. 2018 Nov 26;:

Resection of small bowel adenocarcinoma metastases: Results of the ARCAD-NADEGE cohort study.

Rompteaux P, Gagnière J, Gornet JM, Coriat R, Baumgaertner I, Lecomte T, Afchain P, Zaanan A, Pocard M, Bachet JB, Bonichon-Lamichhane N, Bouché O, Faucheron JL, Forestier J, Lecaille C, Manfredi S, Tougeron D, Terrebonne E, Chehimi M, Villing AL, Sarda C, Legoux JL, Benamouzig R, Aparicio T

Eur J Surg Oncol. 2018 Nov 22;:

Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.

Bennouna J, Hiret S, Bertaut A, Bouché O, Deplanque G, Borel C, François E, Conroy T, Ghiringhelli F, des Guetz G, Seitz JF, Artru P, Hebbar M, Stanbury T, Denis MG, Adenis A, Borg C

JAMA Oncol. 2018 Oct 25;:

Rationale and Design of the IROCAS Study: Multicenter, International, Randomized Phase 3 Trial Comparing Adjuvant Modified (m) FOLFIRINOX to mFOLFOX6 in Patients With High-Risk Stage III (pT4 and/or N2) Colon Cancer-A UNICANCER GI-PRODIGE Trial.

Bennouna J, André T, Campion L, Hiret S, Miglianico L, Mineur L, Touchefeu Y, Artru P, Asmis T, Bouché O, Borde F, Kavan P, Lam YH, Rajpar LS, Emile JF, Jouffroy C, Gill S, Taïeb J

Clin Colorectal Cancer. 2018 Oct 19;:

Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial.

Touchefeu Y, Guimbaud R, Louvet C, Dahan L, Samalin E, Barbier E, Le Malicot K, Cohen R, Gornet JM, Aparicio T, Nguyen S, Azzedine A, Etienne PL, Phelip JM, Hammel P, Chapelle N, Sefrioui D, Mineur L, Lepage C, Bouche O

Gastric Cancer. 2018 Oct 11;:

Dynapenia could predict chemotherapy-induced dose-limiting neurotoxicity in digestive cancer patients.

Botsen D, Ordan MA, Barbe C, Mazza C, Perrier M, Moreau J, Brasseur M, Renard Y, Taillière B, Slimano F, Bertin E, Bouché O

BMC Cancer. 2018 Oct 4;18(1):955

ARCAD-NADEGE cohort: Result of a small bowel adenocarcinomas prospective cohort.

Aparicio T, Manfredi S, Tougeron D, Henriques J, Bouche O, Pezet D, Piessen G, Coriat R, Zaanan A, Legoux JL, Terrebone E, Pocard M, Gornet JM, Vernerey D, Afchain P

Ann. Oncol.. 2018 Oct;29 Suppl 8:viii263

Exploratory analyses of 400 patients enrolled in 2 FFCD trials of first line treatment for metastatic pancreatic cancer.

Taieb J, Phelip JM, Rinaldi Y, Barbier E, Bouche O, Khemissa Akouz F, Gratet A, Petorin C, Miglianico L, Malka D, Laharie Mineur H, Rebischung C, Lepage C, Francois E, Dahan L

Ann. Oncol.. 2018 Oct;29 Suppl 8:viii244

Multicentric retrospective analysis of patients with KIT exon 9 mutated GIST.

Callejo Goena A, Faouzi S, Bouche O, Chevalier T, Isambert N, Duffaud F, Collard O, Mir O, Terrier P, Blay JY, Le Cesne A

Ann. Oncol.. 2018 Oct;29 Suppl 8:viii582

PRODIGE 29-UCGI 26(NEOPAN): A randomised trial of chemotherapy with folfirinox or gemcitabine in locally advanced pancreatic carcinoma (PC).

Ducreux MP, Desgrippes R, Texier M, Di Fiore F, Vanelslander P, Capitain O, Guimbaud R, Forestier J, El Hajbi F, Follana P, Parzy A, Baba Hamed N, Rinaldi Y, Brotelle T, Pignon JP, Jouffroy C, Dahan L, Bouche O

Ann. Oncol.. 2018 Oct;29 Suppl 8:viii266-viii267

Withholding Anti-EGFR: Impact on outcome of RAS wild-type metastatic colorectal tumours (WAIT OR ACT): A multicentric AGEO study.

Palmieri LJ, Mineur L, Tougeron D, Rousseau BJ, Granger V, Gornet JM, Smith D, Lievre A, Galais MP, Racine Doat S, Pernot S, Bignon Bretagne AL, Metges JP, Baba-Hamed N, Hassine M, Obled S, Vitellius C, Bouche O, Vernerey D, Coriat R

Ann. Oncol.. 2018 Oct;29 Suppl 8:viii163

Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC).

Neuzillet C, Gaujoux S, Williet N, Bachet JB, Bauguion L, Colson Durand L, Conroy T, Dahan L, Gilabert M, Huguet F, Marthey L, Meilleroux J, de Mestier L, Napoléon B, Portales F, Sa Cunha A, Schwarz L, Taieb J, Chibaudel B, Bouché O, Hammel P, ,,,,,,,,,

Dig Liver Dis. 2018 Aug 18;:

Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.

Kim S, François E, André T, Samalin E, Jary M, El Hajbi F, Baba-Hamed N, Pernot S, Kaminsky MC, Bouché O, Desrame J, Zoubir M, Ghiringhelli F, Parzy A, De La Fouchardiere C, Smith D, Deberne M, Spehner L, Badet N, Adotevi O, Anota A, Meurisse A, Vernerey D, Taieb J, Vendrely V, Buecher B, Borg C

Lancet Oncol.. 2018 Jul 2;:

Gastric cancer: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO).

Zaanan A, Bouché O, Benhaim L, Buecher B, Chapelle N, Dubreuil O, Fares N, Granger V, Lefort C, Gagniere J, Meilleroux J, Baumann AS, Vendrely V, Ducreux M, Michel P,

Dig Liver Dis. 2018 Jun 6;:

Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials.

Aparicio T, Ducreux M, Faroux R, Barbier E, Manfredi S, Lecomte T, Etienne PL, Bedenne L, Bennouna J, Phelip JM, François E, Michel P, Legoux JL, Gasmi M, Breysacher G, Rougier P, De Gramont A, Lepage C, Bouché O, Seitz JF,

Eur. J. Cancer. 2018 May 25;98:1-9

Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer.

Aparicio T, Bouché O, Francois E, Retornaz F, Barbier E, Taieb J, Kirscher S, Etienne PL, Faroux R, Khemissa Akouz F, El Hajbi F, Locher C, Rinaldi Y, Lecomte T, Lavau-Denes S, Baconnier M, Oden-Gangloff A, Genet D, Bedenne L, Paillaud E,

Eur. J. Cancer. 2018 May 16;97:16-24

Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results.

Aparicio T, Bouché O, Taieb J, Maillard E, Kirscher S, Etienne PL, Faroux R, Khemissa Akouz F, El Hajbi F, Locher C, Rinaldi Y, Lecomte T, Lavau-Denes S, Baconnier M, Oden-Gangloff A, Genet D, Paillaud E, Retornaz F, François E, Bedenne L,

Ann. Oncol.. 2018 Apr 30;:

3 Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial.

André T, Vernerey D, Mineur L, Bennouna J, Desrame J, Faroux R, Fratte S, Hug de Larauze M, Paget-Bailly S, Chibaudel B, Bez J, Dauba J, Louvet C, Lepere C, Dupuis O, Becouarn Y, Mabro M, Egreteau J, Bouche O, Deplanque G, Ychou M, Galais MP, Ghiringhelli F, Dourthe LM, Bachet JB, Khalil A, Bonnetain F, de Gramont A, Taieb J,

J. Clin. Oncol.. 2018 Apr 5;:JCO2017760355

Feasibility of systematic handgrip strength testing in digestive cancer patients treated with chemotherapy: The FIGHTDIGO study.

Ordan MA, Mazza C, Barbe C, Perrier M, Botsen D, Renard Y, Moreau J, Brasseur M, Taillière B, Bertin É, Bouché O

Cancer. 2018 Apr 1;124(7):1501-1506

Phase III randomized trial comparing 5-fluorouracil and oxaliplatin with or without docetaxel in first-line advanced gastric cancer chemotherapy (GASTFOX study).

Zaanan A, Samalin E, Aparicio T, Bouche O, Laurent-Puig P, Manfredi S, Michel P, Monterymard C, Moreau M, Rougier P, Tougeron D, Taieb J, Louvet C

Dig Liver Dis. 2018 Apr;50(4):408-410

Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9).

Aparicio T, Ghiringhelli F, Boige V, Le Malicot K, Taieb J, Bouché O, Phelip JM, François E, Borel C, Faroux R, Dahan L, Jacquot S, Genet D, Khemissa F, Suc E, Desseigne F, Texereau P, Lepage C, Bennouna J,

J. Clin. Oncol.. 2018 Mar 1;36(7):674-681

[Evaluation of the feasibility of a program of adapted physical activity in day hospital of digestive oncology: From the point of view of patients].

Crespel C, Brami C, de Boissieu P, Mazza C, Chauvet K, Lemoine A, Gavlak B, Léandri C, Brasseur M, Bertin E, Bouché O

Bull Cancer. 2018 Mar;105(3):228-233

RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study.

Bachet JB, Bouché O, Taieb J, Dubreuil O, Garcia ML, Meurisse A, Normand C, Gornet JM, Artru P, Louafi S, Bonnetain F, Thirot-Bidault A, Baumgaertner I, Coriat R, Tougeron D, Lecomte T, Mary F, Aparicio T, Marthey L, Taly V, Blons H, Vernerey D, Laurent-Puig P

Ann. Oncol.. 2018 Feb 9;:

LRP1 expression in colon cancer predicts clinical outcome.

Boulagnon-Rombi C, Schneider C, Leandri C, Jeanne A, Grybek V, Bressenot AM, Barbe C, Marquet B, Nasri S, Coquelet C, Fichel C, Bouland N, Bonnomet A, Kianmanesh R, Lebre AS, Bouché O, Diebold MD, Bellon G, Dedieu S

Oncotarget. 2018 Feb 6;9(10):8849-8869

Gastrointestinal lymphomas: French Intergroup clinical practice recommendations for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFH).

Matysiak-Budnik T, Fabiani B, Hennequin C, Thieblemont C, Malamut G, Cadiot G, Bouché O, Ruskoné-Fourmestraux A

Dig Liver Dis. 2018 Feb;50(2):124-131

Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results.

Aparicio T, Bouché O, Taieb J, Maillard E, Kirscher S, Etienne PL, Faroux R, Khemissa Akouz F, El Hajbi F, Locher C, Rinaldi Y, Lecomte T, Lavau-Denes S, Baconnier M, Oden-Gangloff A, Genet D, Paillaud E, Retornaz F, François E, Bedenne L,

Ann. Oncol.. 2018 Jan 1;29(1):133-138

EPIGIST: An observational real-life study on patients with metastatic gastrointestinal stromal tumors receiving imatinib.

Bouché O, Cesne AL, Rios M, Chaigneau L, Italiano A, Duffaud F, Lecomte T, Arsène D, Manfredi S, Aparicio T, Remy S, Isambert N, Collard O, Priou F, Bertucci F, Sambuc R, Bisot-Locard S, Bourges O, Chabaud S, Blay JY

PLoS ONE. 2018 ;13(9):e0204117

Evaluation of Treatment Effect with Paired Failure Times in a Single-Arm Phase II Trial in Oncology.

Texier M, Rotolo F, Ducreux M, Bouché O, Pignon JP, Michiels S

Comput Math Methods Med. 2018 ;2018:1672176

Small bowel adenocarcinoma: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO).

Locher C, Batumona B, Afchain P, Carrère N, Samalin E, Cellier C, Aparicio T, Becouarn Y, Bedenne L, Michel P, Parc Y, Pocard M, Chibaudel B, Bouché O,

Dig Liver Dis. 2018 Jan;50(1):15-19

Value of Contrast-Enhanced Ultrasound Quantification Criteria for Identifying Patients not Responding to Bevacizumab-Based Therapy for Colorectal Liver Metastases.

Tranquart F, Dujardin PA, Bouché O, Marcus C, Borg C, Manzoni P, Douillard JY, Labbe-Devilliers C, Terrebonne E, Smith D, Trillaud H, Capitain O, Aubé C, Spano JP, Lucidarme O, Ferru A, Tasu JP, Manfredi S, Bleuzen A, Léger J, Lecomte T

Ultraschall Med. 2017 Dec 12;:

Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study.

Palle J, Tougeron D, Pozet A, Soularue E, Artru P, Leroy F, Dubreuil O, Sarabi M, Williet N, Manfredi S, Martin-Babau J, Rebischung C, Abdelghani MB, Evesque L, Dreanic J, Hautefeuille V, Louafi S, Sefrioui D, Savinelli F, Mabro M, Rousseau B, Lecaille C, Bouché O, Louvet C, Lecomte T, Bonnetain F, Taieb J, Zaanan A

Oncotarget. 2017 Nov 24;8(60):101383-101393

Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status.

Taieb J, Kourie HR, Emile JF, Le Malicot K, Balogoun R, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Mulot C, Bouché O, Aparicio T, Michel P, Thaler J, Bridgewater J, Van Cutsem E, Perkins G, Lepage C, Salazar R, Laurent-Puig P,

JAMA Oncol. 2017 Nov 22;:

Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer.

Azria D, Doyen J, Jarlier M, Martel-Lafay I, Hennequin C, Etienne P, Vendrely V, François E, de La Roche G, Bouché O, Mirabel X, Denis B, Mineur L, Berdah J, Mahé M, Bécouarn Y, Dupuis O, Lledo G, Seitz J, Bedenne L, Gourgou-Bourgade S, Juzyna B, Conroy T, Gérard J

Ann. Oncol.. 2017 Oct;28(10):2436-2442

Retrospective Analysis of CA19-9 Decrease in Patients with Metastatic Pancreatic Carcinoma Treated with FOLFIRINOX or Gemcitabine in a Randomized Phase III Study (ACCORD11/PRODIGE4).

Robert M, Jarlier M, Gourgou S, Desseigne F, Ychou M, Bouché O, Juzyna B, Conroy T, Bennouna J

Oncology. 2017 Oct;93(6):

Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment.

Thierry AR, El Messaoudi S, Mollevi C, Raoul JL, Guimbaud R, Pezet D, Artru P, Assenat E, Borg C, Mathonnet M, De La Fouchardière C, Bouché O, Gavoille C, Fiess C, Auzemery B, Meddeb R, Lopez-Crapez E, Sanchez C, Pastor B, Ychou M

Ann. Oncol.. 2017 Sep;28(9):2149-2159

Digestive System Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms.

de Mestier L, Cros J, Neuzillet C, Hentic O, Egal A, Muller N, Bouché O, Cadiot G, Ruszniewski P, Couvelard A, Hammel P

Neuroendocrinology. 2017 Aug;:

Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study).

Kim S, Jary M, André T, Vendrely V, Buecher B, François E, Bidard FC, Dumont S, Samalin E, Peiffert D, Pernot S, Baba-Hamed N, El Hajbi F, Bouché O, Desrame J, Parzy A, Zoubir M, Louvet C, Bachet JB, Nguyen T, Abdelghani MB, Smith D, De La Fouchardière C, Aparicio T, Bennouna J, Gornet JM, Jacquin M, Bonnetain F, Borg C

BMC Cancer. 2017 Aug;17(1):574

Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib.

Joensuu H, Blay JY, Comandone A, Martin-Broto J, Fumagalli E, Grignani G, Del Muro XG, Adenis A, Valverde C, Pousa AL, Bouché O, Italiano A, Bauer S, Barone C, Weiss C, Crippa S, Camozzi M, Castellana R, Le Cesne A

Br. J. Cancer. 2017 Aug;:

Health-related quality of life results from the PRODIGE 5/ACCORD 17 randomised trial of FOLFOX versus fluorouracil-cisplatin regimen in oesophageal cancer.

Bascoul-Mollevi C, Gourgou S, Galais MP, Raoul JL, Bouché O, Douillard JY, Adenis A, Etienne PL, Juzyna B, Bedenne L, Conroy T

Eur. J. Cancer. 2017 Aug;84:239-249

Prognostic value of primary tumor location in stage III colon cancer is associated with RAS and BRAF mutational status.

Taieb J, Kourie Hampig R, Emile Jean F, Le Malicot K, Balogoun R, Tabernero J, Mini E, Folprecht G, Van Laethem Jean L, Mulot C, Bouché O, Aparicio T, Michel P, Thaler J, Bridgewater J, Van Cutsem E, Perkins G, Lepage C, Salazar R, Laurent Puig P

Ann. Oncol.. 2017 Jun;28 Suppl 3:iii142

Anal cancer: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Moureau-Zabotto L, Vendrely V, Abramowitz L, Borg C, Francois E, Goere D, Huguet F, Peiffert D, Siproudhis L, Ducreux M, Bouché O

Dig Liver Dis. 2017 May;:

Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer.

Taieb J, Le Malicot K, Shi Q, Penault Lorca F, Bouché O, Tabernero J, Mini E, Goldberg RM, Folprecht G, Luc Van Laethem J, Sargent DJ, Alberts SR, Francois Emile J, Laurent Puig P, Sinicrope FA

J. Natl. Cancer Inst.. 2017 May;109(5):

Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects.

Pernot S, Badoual C, Terme M, Castan F, Cazes A, Bouche O, Bennouna J, Francois E, Ghiringhelli F, De La Fouchardiere C, Samalin E, Bachet JB, Borg C, Ducreux M, Marcheteau E, Stanbury T, Gourgou S, Malka D, Taieb J

Eur. J. Cancer. 2017 Apr;79:15-22

Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma.

Vienot A, Beinse G, Louvet C, de Mestier L, Meurisse A, Fein F, Heyd B, Cleau D, d'Engremont C, Dupont-Gossart AC, Lakkis Z, Tournigand C, Bouché O, Rousseau B, Neuzillet C, Bonnetain F, Borg C, Vernerey D

J. Natl. Cancer Inst.. 2017 Apr;:

Patterns of care and clinical outcomes in primary oesophageal gastrointestinal stromal tumours (GIST): A retrospective study of the French Sarcoma Group (FSG).

Duffaud F, Meeus P, Bertucci F, Delhorme JB, Stoeckle E, Isambert N, Bompas E, Gagniere J, Bouché O, Toulmonde M, Salas S, Blay JY, Bonvalot S,

Eur J Surg Oncol. 2017 Apr;:

Rectal cancer: French Intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO).

Gérard JP, André T, Bibeau F, Conroy T, Legoux JL, Portier G, Bosset JF, Cadiot G, Bouché O, Bedenne L,

Dig Liver Dis. 2017 Apr;49(4):359-367

A possible association of baseline serum IL-17A concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimen.

Lereclus E, Tout M, Girault A, Baroukh N, Caulet M, Borg C, Bouché O, Ternant D, Paintaud G, Lecomte T, Raoul W

BMC Cancer. 2017 Mar;17(1):220

Geriatric factors analyses from FFCD 2001-02 phase III study of first-line chemotherapy for elderly metastatic colorectal cancer patients.

Aparicio T, Gargot D, Teillet L, Maillard E, Genet D, Cretin J, Locher C, Bouché O, Breysacher G, Seitz JF, Gasmi M, Stefani L, Ramdani M, Lecomte T, Auby D, Faroux R, Bachet JB, Lepère C, Khemissa F, Sobhani I, Boulat O, Mitry E, Jouve JL,

Eur. J. Cancer. 2017 Mar;74:98-108

Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients.

Caulet M, Lecomte T, Bouché O, Rollin J, Gouilleux-Gruart V, Azzopardi N, Léger J, Borg C, Douillard JY, Manfredi S, Smith D, Capitain O, Ferru A, Moussata D, Terrebone E, Paintaud G, Ternant D

Clin Pharmacokinet. 2016 Nov;55(11):1381-1394

Capecitabine and adermatoglyphia: trouble in border!

Mazza C, Slimano F, Visseaux L, Ordan MA, Botsen D, Grange F, Bouche O

J Eur Acad Dermatol Venereol. 2016 Nov;:

Is antihistaminergic H2 really useful in prevention of hypersensitivity induced by paclitaxel?

Slimano F, Coliat P, Perotin JM, Vella-Boucaud J, Mongaret C, Bouché O

Support Care Cancer. 2016 Nov;24(11):4475-7

Prognostic value of baseline seric Syndecan-1 in initially unresectable metastatic colorectal cancer patients: a simple biological score.

Jary M, Lecomte T, Bouché O, Kim S, Dobi E, Queiroz L, Ghiringhelli F, Etienne H, Léger J, Godet Y, Balland J, Lakkis Z, Adotevi O, Bonnetain F, Borg C, Vernerey D

Int. J. Cancer. 2016 Nov;139(10):2325-35

Signet Ring Cells and Efficacy of First-line Chemotherapy in Advanced Gastric or Oesogastric Junction Adenocarcinoma.

Lemoine N, Adenis A, Bouche O, Duhamel A, Heurgue A, Leteurtre E, Amela E, Salleron J, Hebbar M

Anticancer Res.. 2016 10;36(10):5543-5549

Feasibility of Capecitabine and Oxaliplatin Combination Chemotherapy Without Central Venous Access Device in Patients With Stage III Colorectal Cancer.

Lapeyre-Prost A, Hug de Larauze M, Chibaudel B, Garcia ML, Guering-Meyer V, Bouché O, Boucher E, Ychou M, Dauba J, Obled S, Lièvre A, Malka D, Faroux R, Bonnet I, Taieb J, André T,

Clin Colorectal Cancer. 2016 Sep;15(3):250-6

Joint model for left-censored longitudinal data, recurrent events and terminal event: Predictive abilities of tumor burden for cancer evolution with application to the FFCD 2000-05 trial.

Król A, Ferrer L, Pignon JP, Proust-Lima C, Ducreux M, Bouché O, Michiels S, Rondeau V

Biometrics. 2016 Sep;72(3):907-16

Recent insights in the therapeutic management of patients with gastric cancer.

de Mestier L, Lardière-Deguelte S, Volet J, Kianmanesh R, Bouché O

Dig Liver Dis. 2016 Sep;48(9):984-94

A Study of Hypermethylated Circulating Tumor DNA as a Universal Colorectal Cancer Biomarker.

Garrigou S, Perkins G, Garlan F, Normand C, Didelot A, Le Corre D, Peyvandi S, Mulot C, Niarra R, Aucouturier P, Chatellier G, Nizard P, Perez-Toralla K, Zonta E, Charpy C, Pujals A, Barau C, Bouché O, Emile JF, Pezet D, Bibeau F, Hutchison JB, Link DR, Zaanan A, Laurent-Puig P, Sobhani I, Taly V

Clin. Chem.. 2016 Aug;62(8):1129-39

Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial.

Hammel P, Huguet F, van Laethem JL, Goldstein D, Glimelius B, Artru P, Borbath I, Bouché O, Shannon J, André T, Mineur L, Chibaudel B, Bonnetain F, Louvet C,

JAMA. 2016 May;315(17):1844-53

Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial.

Mir O, Cropet C, Toulmonde M, Cesne AL, Molimard M, Bompas E, Cassier P, Ray-Coquard I, Rios M, Adenis A, Italiano A, Bouché O, Chauzit E, Duffaud F, Bertucci F, Isambert N, Gautier J, Blay JY, Pérol D,

Lancet Oncol.. 2016 May;17(5):632-41

Efficacy of modern chemotherapy and prognostic factors in patients with ovarian metastases from gastric cancer: A retrospective AGEO multicentre study.

Brieau B, Auzolle C, Pozet A, Tougeron D, Bouché O, Soibinet P, Coriat R, Prieux C, Lecomte T, Goujon G, Marthey L, Rougier P, Bonnetain F, Ducreux M, Taieb J, Zaanan A

Dig Liver Dis. 2016 Apr;48(4):441-5

Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours in a real-life setting.

Bouchet S, Poulette S, Titier K, Moore N, Lassalle R, Abouelfath A, Italiano A, Chevreau C, Bompas E, Collard O, Duffaud F, Rios M, Cupissol D, Adenis A, Ray-Coquard I, Bouché O, Le Cesne A, Bui B, Blay JY, Molimard M

Eur. J. Cancer. 2016 Apr;57:31-8

Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study).

Ricotta R, Verrioli A, Ghezzi S, Porcu L, Grothey A, Falcone A, Van Cutsem E, Argilés G, Adenis A, Ychou M, Barone C, Bouché O, Peeters M, Humblet Y, Mineur L, Sobrero AF, Hubbard JM, Cremolini C, Prenen H, Tabernero J, Jarraya H, Mazard T, Deguelte-Lardiere S, Papadimitriou K, Van den Eynde M, Pastorino A, Redaelli D, Bencardino K, Funaioli C, Amatu A, Carlo-Stella G, Torri V, Sartore-Bianchi A, Vanzulli A, Siena S

ESMO Open. 2016 ;1(6):e000111

Incidental gastrointestinal 18F-Fluorodeoxyglucose uptake associated with lung cancer.

Vella-Boucaud J, Papathanassiou D, Bouche O, Prevost A, Lestra T, Dury S, Vallerand H, Perotin JM, Launois C, Boissiere L, Brasseur M, Lebargy F, Deslee G

BMC Pulm Med. 2015 Dec;15:152

Prevalence of hepatitis B and C and sensibility of a selective screening questionnaire in patients receiving chemotherapy for solid tumors.

Brasseur M, Heurgué-Berlot A, Barbe C, Brami C, Rey JB, Vella-Boucaud J, Dabouz F, Deslée G, Grange F, Volet J, Bouché O

BMC Cancer. 2015 Dec;15:999

Reversible sarcopenia in patients with gastrointestinal stromal tumor treated with imatinib.

Moryoussef F, Dhooge M, Volet J, Barbe C, Brezault C, Hoeffel C, Coriat R, Bouché O

J Cachexia Sarcopenia Muscle. 2015 Dec;6(4):343-50

High-dose FOLFIRI plus bevacizumab in the treatment of metastatic colorectal cancer patients with two different UGTA1 genotypes: FFCD 0504 study.

Manfredi S, Bouche O, Rougier P, Dahan L, Loriot MA, Aparicio T, Etienne PL, Lafargue JP, Lecaille C, Legoux LL, Le Malicot K, Maillard E, Lecomte T, Khemissa F, Breysacher G, Michel P, Mitry E, Bedenne L

Mol Cancer Ther. 2015 Oct 22. pii: molcanther.0293.2015.

Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02)dagger.

Aparicio T, Lavau-Denes S, Phelip JM, Maillard E, Jouve JL, Gargot D, Gasmi M, Locher C, Adhoute X, Michel P, Khemissa F, Lecomte T, Provencal J, Breysacher G, Legoux JL, Lepere C, Charneau J, Cretin J, Chone L, Azzedine A, Bouche O, Sobhani I, Bedenne L, Mitry E

Ann Oncol. 2015 Oct 20. pii: mdv491.

MR imaging of pelvic extraperitoneal masses: A diagnostic approach.

Janvier A, Rousset P, Cazejust J, Bouche O, Soyer P, Hoeffel C

Diagn Interv Imaging. 2015 Sep 21. pii: S2211-5684(15)00256-9

[Anti-angiogenic treatments in metastatic colorectal cancer: Does a continuous angiogenic blockade make sense?].

Jary M, Borg C, Bouche O, Kim S, Andre T, Bennouna J

Bull Cancer. 2015 Sep;102(9):758-71

A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients.

Van Cutsem E, Prenen H, D'Haens G, Bennouna J, Carrato A, Ducreux M, Bouche O, Sobrero A, Latini L, Staines H, Oum'Hamed Z, Dressler H, Studeny M, Capdevila J

Ann Oncol. 2015 Aug 12. pii: mdv286.

Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.

Tabernero J, Lenz HJ, Siena S, Sobrero A, Falcone A, Ychou M, Humblet Y, Bouche O, Mineur L, Barone C, Adenis A, Yoshino T, Goldberg RM, Sargent DJ, Wagner A, Laurent D, Teufel M, Jeffers M, Grothey A, Van Cutsem E

Lancet Oncol. 2015 Aug;16(8):937-48

Early surgery for failure after chemoradiation in operable thoracic oesophageal cancer. Analysis of the non-randomised patients in FFCD 9102 phase III trial: Chemoradiation followed by surgery versus chemoradiation alone.

Vincent J, Mariette C, Pezet D, Huet E, Bonnetain F, Bouche O, Conroy T, Roullet B, Seitz JF, Herr JP, Di Fiore F, Jouve JL, Bedenne L

Eur J Cancer. 2015 Jul 7. pii: S0959-8049(15)00495-5

Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer: The FFCD PRODIGE 13 randomised phase III trial.

Lepage C, Phelip JM, Cany L, Faroux R, Manfredi S, Ain JF, Pezet D, Baconnier M, Deguiral P, Terrebone E, Adenis A, Le Malicot K, Bedenne L, Bouche O

Dig Liver Dis. 2015 Apr 2. pii: S1590-8658(15)00265-0

Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.

,Thaler J, Greil R, Gaenzer J, Eisterer W, Tschmelitsch J, Samonigg H, Zabernigg A, Schmid F, Steger G, Steinacher R, Andel J, Lang A, Függer R, Hofbauer F, Woell E, Geissler D, Lenauer A, Prager M, Van Laethem JL, Van Cutsem E, D'Haens G, Demolin G, Kerger J, Deboever G, Ghillebert G, Polus M, Van Cutsem E, RezaieKalantari H, Delaunoit T, Goeminne JC, Peeters M, Vergauwe P, Houbiers G, Humblet Y, Janssens J, Schrijvers D, Vanderstraeten E, Van Laethem JL, Vermorken J, Van Daele D, Ferrante M, Forget F, Hendlisz A, Yilmaz M, Nielsen SE, Vestermark L, Larsen J, Ychou M, Zawadi A, Zawadi MA, Bouche O, Mineur L, Bennouna-Louridi J, Dourthe LM, Ychou M, Boucher E, Taieb J, Pezet D, Desseigne F, Ducreux M, Texereau P, Miglianico L, Rougier P, Fratte S, Levache CB, Merrouche Y, Ellis S, Locher C, Ramee JF, Garnier C, Viret F, Chauffert B, Cojean-Zelek I, Michel P, Lecaille C, Borel C, Seitz JF, Smith D, Lombard-Bohas C, Andre T, Gornet JM, Fein F, Coulon-Sfairi MA, Kaminsky MC, Lagasse JP, Luet D, Etienne PL, Gasmi M, Vanoli A, Nguyen S, Aparicio T, Perrier H, Stremsdoerfer N, Laplaige P, Arsene D, Auby D, Bedenne L, Coriat R, Denis B, Geoffroy P, Piot G, Becouarn Y, Bordes G, Deplanque G, Dupuis O, Fruge F, Guimbaud R, Lecomte T, Lledo G, Sobhani I, Asnacios A, Azzedine A, Desauw C, Galais MP, Gargot D, Lam YH, Abakar-Mahamat A, Berdah JF, Catteau S, Clavero-Fabri MC, Codoul JF, Legoux JL, Goldfain D, Guichard P, Verge DP, Provencal J, Vedrenne B, Brezault-Bonnet C, Cleau D, Desir JP, Fallik D, Garcia B, Gaspard MH, Genet D, Hartwig J, Krummel Y, MatysiakBudnik T, Palascak-Juif V, Randrianarivelo H, Rinaldi Y, Aleba A, Darut-Jouve A, de Gramont A, Hamon H, Wendehenne F, Matzdorff A, Stahl MK, Schepp W, Burk M, Mueller L, Folprecht G, Geissler M, Mantovani-Loeffler L, Hoehler T, Asperger W, Kroening H, von Weikersthal LF, Fuxius S, Groschek M, Meiler J, Trarbach T, Rauh J, Ziegenhagen N, Kretzschmar A, Graeven U, Nusch A, von Wichert G, Hofheinz RD, Kleber G, Schmidt KH, Vehling-Kaiser U, Baum C, Schuette J, Haag GM, Holtkamp W, Potenberg J, Reiber T, Schliesser G, Schmoll HJ, Schneider-Kappus W, Abenhardt W, Denzlinger C, Henning J, Marxsen B, GuenterDerigs H, Lambertz H, Becker-Boost I, Caca K, Constantin C, Decker T, Eschenburg H, Gabius S, Hebart H, Hoffmeister A, Horst HA, Kremers S, Leithaeuser M, Mueller S, Wagner S, Daum S, Schlegel F, Stauch M, Heinemann V, Labianca R, Colucci G, Amadori D, Mini E, Falcone A, Boni C, Maiello E, Latini L, Zaniboni A, Amadori D, Aprile G, Barni S, Mattioli R, Martoni A, Passalacqua R, Nicolini M, Pasquini E, Rabbi C, Aitini E, Ravaioli A, Barone C, Biasco G, Tamberi S, Gambi A, Verusio C, Marzola M, Lelli G, Boni C, Cascinu S, Bidoli P, Vaghi M, Cruciani G, Di Costanzo F, Sobrero A, Mini E, Petrioli R, Aglietta M, Alabiso O, Capuzzo F, Falcone A, Corsi DC, Labianca R, Salvagni S, Chiara S, Ferraù F, Giuliani F, Lonardi S, Gebbia N, Mantovani G, Sanches E, Sanches E, Mellidez JC, Santos P, Freire J, Sarmento C, Costa L, Pinto AM, Barroso S, Santo JE, Guedes F, Monteiro A, Sa A, Furtado I, Tabernero J, Salazar R, Aguilar EA, Herrero FR, Tabernero J, Valera JS, ValladaresAyerbes M, FeliuBatlle J, Gil S, Garcia-Giron C, Vivanco GL, Salvia AS, Orduña VA, Garcia RV, Gallego J, Sureda BM, Remon J, Safont Aguilera MJ, CireraNogueras L, Merino B, Castro CG, de Prado PM, PijaumePericay C, ConstenlaFigueiras M, Jordan I, GomeReina MJ, Garcia AL, Garcia-Ramos AA, Cervantes A, Martos CF, MarcuelloGaspar E, Montero IC, Emperador PE, Carbonero AL, Castillo MG, Garcia TG, Lopez JG, Flores EG, GuillotMorales M, LlanosMuñoz M, Martín AL, Maurel J, Camara JC, Garcia RD, Salgado M, HernandezBusquier I, Ruiz TC, LacastaMuñoa A, Aliguer M, Ortiz de Taranco AV, Ureña MM, Gaspa FL, Ponce JJ, Roig CB, Jimenez PV, GalanBrotons A, AlbiolRodriguez S, Martinez JA, Ruiz LC, CentellesRuiz M, Bridgewater J, Glynne-Jones R, Tahir S, Hickish T, Cassidy J, Samuel L

Ann. Oncol.. 2015 Apr;26(4):822-825

BRAFV600E Gene Mutation in Colonic Adenocarcinomas. Immunohistochemical Detection Using Tissue Microarray and Clinicopathologic Characteristics: A 86 Case Series.

Boulagnon C, Dudez O, Beaudoux O, Dalstein V, Kianmanesh R, Bouche O, Diebold MD

Appl Immunohistochem Mol Morphol. 2015 Feb 21.

FOLFIRI+bevacizumab induction chemotherapy followed by bevacizumab or observation in metastatic colorectal cancer, a phase III trial (PRODIGE 9 - FFCD 0802).

Aparicio T, Linot B, Le Malicot K, Bouche O, Boige V, Francois E, Ghiringhelli F, Legoux JL, Abdelghani MB, Phelip JM, Faroux R, Dahan L, Taieb J, Bedenne L

Dig Liver Dis. 2015 Jan 20. pii: S1590-8658(15)00168-1

Is primary tumour resection associated with survival improvement in patients with colorectal cancer and unresectable synchronous metastases? A pooled analysis of individual data from four randomised trials.

Faron M, Pignon JP, Malka D, Bourredjem A, Douillard JY, Adenis A, Elias D, Bouche O, Ducreux M

Eur J Cancer. 2015 Jan;51(2):166-76

Optimal cut points for quality of life questionnaire-core 30 (QLQ-C30) scales: utility for clinical trials and updates of prognostic systems in advanced hepatocellular carcinoma.

Diouf M, Bonnetain F, Barbare JC, Bouche O, Dahan L, Paoletti X, Filleron T

Oncologist. 2015 Jan;20(1):62-71

Prognostic Value of Angiopoietin-2 for death risk stratification in Patients with Metastatic Colorectal Carcinoma.

Jary M, Vernerey D, Lecomte T, Dobi E, Ghiringhelli F, Monnien F, Godet Y, Kim S, Bouche O, Fratte S, Goncalves A, Leger J, Queiroz L, Adotevi O, Bonnetain F, Borg C

Cancer Epidemiol Biomarkers Prev. 2015 Jan 12. pii: cebp.1059.2014.

Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Féd

Guimbaud R, Louvet C, Ries P, Ychou M, Maillard E, André T, Gornet JM, Aparicio T, Nguyen S, Azzedine A, Etienne PL, Boucher E, Rebischung C, Hammel P, Rougier P, Bedenne L, Bouché O

J. Clin. Oncol.. 2014 Nov;32(31):3520-6

Conservative surgery vs. duodeneopancreatectomy in primary duodenal gastrointestinal stromal tumors (GIST): a retrospective review of 114 patients from the French sarcoma group (FSG).

Duffaud F, Meeus P, Bachet JB, Cassier P, Huynh TK, Boucher E, Bouche O, Moutardier V, le Cesne A, Landi B, Marchal F, Bay JO, Bertucci F, Spano JP, Stoeckle E, Collard O, Chaigneau L, Isambert N, Lebrun-Ly V, Mancini J, Blay JY, Bonvalot S

Eur J Surg Oncol. 2014 Oct;40(10):1369-75

632PEFFICACY AND SAFETY OF PERIOPERATIVE CHEMOTHERAPY WITH 5FU-CISPLATIN-CETUXIMAB IN GASTRIC AND GASTROESOPHAGEAL JUNCTION ADENOCARCINOMAS (GGOJA): A SINGLE ARM MULTICENTRE PHASE II TRIAL (FFCD 0901).

Mariette C, Piessen G, Monterymard C, Pezet D, Ferru A, Baconnier M, Adhoute X, Tavan D, Lepage C, Bouché O

Ann. Oncol.. 2014 Sep;25(suppl_4):iv216

A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy.

Saridaki Z, Weidhaas JB, Lenz HJ, Laurent-Puig P, Jacobs B, De Schutter J, De Roock W, Salzman DW, Zhang W, Yang D, Pilati C, Bouche O, Piessevaux H, Tejpar S

Clin Cancer Res. 2014 Sep 1;20(17):4499-510

Clinical relevance of KRAS-mutated sub-clones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy.

Laurent-Puig P, Pekin D, Normand C, K Kotsopoulos S, Nizard P, Perez Toralla K, Rowell R, Olson J, Srinivasan P, Le Corre D, Hor T, El Harrak Z, Li X, Link D, Bouche O, Emile JF, Landi B, Boige V, Hutchison B, Taly V

Clin Cancer Res. 2014 Sep 23. pii: clincanres.0983.2014.

Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial.

Adenis A, Blay JY, Bui-Nguyen B, Bouche O, Bertucci F, Isambert N, Bompas E, Chaigneau L, Domont J, Ray-Coquard I, Blesius A, Van Tine BA, Bulusu VR, Dubreuil P, Mansfield CD, Acin Y, Moussy A, Hermine O, Le Cesne A

Ann Oncol. 2014 Sep;25(9):1762-9

Infrared spectral histopathology for cancer diagnosis: a novel approach for automated pattern recognition of colon adenocarcinoma.

Nallala J, Diebold MD, Gobinet C, Bouche O, Sockalingum GD, Piot O, Manfait M

Analyst. 2014 Aug 21;139(16):4005-15

Value of diffusion-weighted and gadolinium-enhanced MRI for the diagnosis of pelvic recurrence from colorectal cancer.

Colosio A, Soyer P, Rousset P, Barbe C, Nguyen F, Bouche O, Hoeffel C

J Magn Reson Imaging. 2014 Aug;40(2):306-13

Hsa-miR-31-3p expression is linked to progression-free survival in patients with KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapy.

Manceau G, Imbeaud S, Thiebaut R, Liebaert F, Fontaine K, Rousseau F, Genin B, Le Corre D, Didelot A, Vincent M, Bachet JB, Chibaudel B, Bouche O, Landi B, Bibeau F, Leroy K, Penault-Llorca F, Van Laethem JL, Demetter P, Tejpar S, Rossi S, Mosakhani N, Osterlund P, Ristamaki R, Sarhadi V, Knuutila S, Boige V, Andre T, Laurent-Puig P

Clin Cancer Res. 2014 Jun 15;20(12):3338-47

Is primary tumor resection associated with a longer survival in colon cancer and unresectable synchronous metastases? A 4-year multicentre experience.

de Mestier L, Neuzillet C, Pozet A, Desot E, Deguelte-Lardière S, Volet J, Karoui M, Kianmanesh R, Bonnetain F, Bouché O

Eur J Surg Oncol. 2014 Jun;40(6):685-91

Primary tumor resection in colorectal cancer with unresectable synchronous metastases: A review.

de Mestier L, Manceau G, Neuzillet C, Bachet JB, Spano JP, Kianmanesh R, Vaillant JC, Bouche O, Hannoun L, Karoui M

World J Gastrointest Oncol. 2014 Jun 15;6(6):156-69

[External review of integrative oncology or complementary therapies use. Based on US academic cancer center].

Brami C, Bouche O, Karp JC, Cure H

Bull Cancer. 2014 Jun;101(6):531-2

Primary rectal cancer local staging.

Hoeffel C, Mule S, Laurent V, Bouche O, Volet J, Soyer P

Diagn Interv Imaging. 2014 May;95(5):485-94

Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial.

Conroy T, Galais MP, Raoul JL, Bouche O, Gourgou-Bourgade S, Douillard JY, Etienne PL, Boige V, Martel-Lafay I, Michel P, Llacer-Moscardo C, Francois E, Crehange G, Abdelghani MB, Juzyna B, Bedenne L, Adenis A

Lancet Oncol. 2014 Mar;15(3):305-14

Filiform polyposis: A benign entity? Case report and literature review.

Boulagnon C, Jazeron JF, Diaz-Cives A, Ehrhard F, Bouche O, Diebold MD

Pathol Res Pract. 2014 Mar;210(3):189-93

Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial.

Samalin E, Bouche O, Thezenas S, Francois E, Adenis A, Bennouna J, Taieb J, Desseigne F, Seitz JF, Conroy T, Galais MP, Assenat E, Crapez E, Poujol S, Bibeau F, Boissiere F, Laurent-Puig P, Ychou M, Mazard T

Br J Cancer. 2014 Mar 4;110(5):1148-54

Infrared and Raman imaging for characterizing complex biological materials: a comparative morpho-spectroscopic study of colon tissue.

Nallala J, Piot O, Diebold MD, Gobinet C, Bouche O, Manfait M, Sockalingum GD

Appl Spectrosc. 2014 Jan;68(1):57-68

Primary localized rectal/pararectal gastrointestinal stromal tumors: results of surgical and multimodal therapy from the French Sarcoma group.

Huynh TK, Meeus P, Cassier P, Bouche O, Lardiere-Deguelte S, Adenis A, Andre T, Mancini J, Collard O, Montemurro M, Bompas E, Rios M, Isambert N, Cupissol D, Blay JY, Duffaud F

BMC Cancer. 2014 Mar 5;14:156

Liver angulometry: a simple method to estimate liver volume and ratios.

Kianmanesh R, Piardi T, Tamby E, Parvanescu A, Bruno O, Palladino E, Bouché O, Msika S, Sommacale D

HPB (Oxford). 2013 Dec;15(12):976-84

Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients.

Taly V, Pekin D, Benhaim L, Kotsopoulos SK, Le Corre D, Li X, Atochin I, Link DR, Griffiths AD, Pallier K, Blons H, Bouche O, Landi B, Hutchison JB, Laurent-Puig P

Clin Chem. 2013 Dec;59(12):1722-31

Laparoscopic thermal ablation of splenic metastases initial experience and present aspects.

Lardiere-Deguelte S, de Mestier L, Amroun KL, Volet J, Cart P, Bouche O, Kianmanesh A

J Visc Surg. 2013 Nov;150(5):355-8

Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis.

Paoletti X, Oba K, Bang YJ, Bleiberg H, Boku N, Bouche O, Catalano P, Fuse N, Michiels S, Moehler M, Morita S, Ohashi Y, Ohtsu A, Roth A, Rougier P, Sakamoto J, Sargent D, Sasako M, Shitara K, Thuss-Patience P, Van Cutsem E, Burzykowski T, Buyse M

J Natl Cancer Inst. 2013 Nov 6;105(21):1667-70

Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial.

Bidard FC, Huguet F, Louvet C, Mineur L, Bouche O, Chibaudel B, Artru P, Desseigne F, Bachet JB, Mathiot C, Pierga JY, Hammel P

Ann Oncol. 2013 Aug;24(8):2057-61

Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study.

Huguet F, Van Laethem JL, Goldstein D, Glimelius B, Artru P, Borbath I, Bouche O, Shannon J, André T, Mineur L, Chibaudel B, Bonnetain F, Louvet C

J. Clin. Oncol.. 2013 Jun;31(18_suppl):LBA4003

A randomised phase III intergroup trial comparing high-dose infusional 5-fluorouracil with or without folinic acid with standard bolus 5-fluorouracil/folinic acid in the adjuvant treatment of stage III colon cancer: the Pan-European Trial in Adjuvant Colo

Köhne CH, Bedenne L, Carrato A, Bouché O, Popov I, Gaspà L, Valladares M, Rougier P, Gog C, Reichardt P, Wils J, Pignatti F, Biertz F

Eur. J. Cancer. 2013 May;49(8):1868-75

Taking into account successive treatment lines in the analysis of a colorectal cancer randomised trial.

Penichoux J, Michiels S, Bouche O, Etienne PL, Texereau P, Auby D, Rougier P, Ducreux M, Pignon JP

Eur J Cancer. 2013 May;49(8):1882-8

[Cutaneous adverse reactions of EGFR (epidermal growth factor receptor)-inhibitors: therapeutic algorithm of the French PROCUR group].

Bachmeyer C, Reguiai Z, Peuvrel L, Bachet JB, Bensadoun RJ, Ychou M, Andre T, Bouche O, Dreno B

Bull Cancer. 2013 May;100(5):417-26

Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patients.

Aparicio T, Jouve JL, Teillet L, Gargot D, Subtil F, Le Brun-Ly V, Cretin J, Locher C, Bouche O, Breysacher G, Charneau J, Seitz JF, Gasmi M, Stefani L, Ramdani M, Lecomte T, Mitry E

J Clin Oncol. 2013 Apr 10;31(11):1464-70

Prognostic factors in patients with non resectable metastatic colorectal cancer in the era of targeted biotherapies: relevance of Kohne's risk classification.

Desot E, de Mestier L, Volet J, Delmas C, Garcia B, Geoffroy P, Abdelli N, Baule M, Dubroeucq O, Marquis E, Bouche O

Dig Liver Dis. 2013 Apr;45(4):330-5

Survey on the management of skin toxicity associated with EGFR inhibitors amongst French physicians.

Peuvrel L, Bachmeyer C, Reguiai Z, Bachet JB, André T, Bensadoun RJ, Bouché O, Ychou M, Dréno B,

J Eur Acad Dermatol Venereol. 2013 Apr;27(4):419-29

Infrared imaging as a cancer diagnostic tool: introducing a new concept of spectral barcodes for identifying molecular changes in colon tumors.

Nallala J, Piot O, Diebold MD, Gobinet C, Bouche O, Manfait M, Sockalingum GD

Cytometry A. 2013 Mar;83(3):294-300

The added value of quality of life (QoL) for prognosis of overall survival in patients with palliative hepatocellular carcinoma.

Diouf M, Filleron T, Barbare JC, Fin L, Picard C, Bouche O, Dahan L, Paoletti X, Bonnetain F

J Hepatol. 2013 Mar;58(3):509-21

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.

Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, Van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C, Steffens CC, Alonso-Orduña V, Schlichting C, Reyes-Rivera I, Bendahmane B, André T, Kubicka S,

Lancet Oncol.. 2013 Jan;14(1):29-37

Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial.

Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Boige V, Berille J, Conroy T

J Clin Oncol. 2013 Jan 1;31(1):23-9

Impact of primary tumour resection on survival of patients with colorectal cancer and synchronous metastases treated by chemotherapy: results from the multicenter, randomised trial Federation Francophone de Cancerologie Digestive 9601.

Ferrand F, Malka D, Bourredjem A, Allonier C, Bouche O, Louafi S, Boige V, Mousseau M, Raoul JL, Bedenne L, Leduc B, Deguiral P, Faron M, Pignon JP, Ducreux M

Eur J Cancer. 2013 Jan;49(1):90-7

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouche O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D

Lancet. 2013 Jan 26;381(9863):303-12

Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer.

Gerard JP, Azria D, Gourgou-Bourgade S, Martel-Lafay I, Hennequin C, Etienne PL, Vendrely V, Francois E, de La Roche G, Bouche O, Mirabel X, Denis B, Mineur L, Berdah JF, Mahe MA, Becouarn Y, Dupuis O, Lledo G, Seitz JF, Bedenne L, Juzyna B, Conroy T

J Clin Oncol. 2012 Dec 20;30(36):4558-65

Serum creatine kinase increase in patients treated with tyrosine kinase inhibitors for solid tumors.

Adenis A, Bouché O, Bertucci F, Kalbacher E, Fournier C, Cassier P, Collard O, Bay JO, Italiano A, Chevreau C, Clisant S, Kramar A, Blay JY, Penel N

Med. Oncol.. 2012 Dec;29(4):3003-8

Infrared spectral imaging as a novel approach for histopathological recognition in colon cancer diagnosis.

Nallala J, Gobinet C, Diebold MD, Untereiner V, Bouche O, Manfait M, Sockalingum GD, Piot O

J Biomed Opt. 2012 Nov;17(11):116013

Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTs.

Emile JF, Brahimi S, Coindre JM, Bringuier PP, Monges G, Samb P, Doucet L, Hostein I, Landi B, Buisine MP, Neuville A, Bouche O, Cervera P, Pretet JL, Tisserand J, Gauthier A, Le Cesne A, Sabourin JC, Scoazec JY, Bonvalot S, Corless CL, Heinrich MC, Blay JY, Aegerter P

Med Oncol. 2012 Sep;29(3):1765-72

Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era.

Cassier PA, Fumagalli E, Rutkowski P, Schoffski P, Van Glabbeke M, Debiec-Rychter M, Emile JF, Duffaud F, Martin-Broto J, Landi B, Adenis A, Bertucci F, Bompas E, Bouche O, Leyvraz S, Judson I, Verweij J, Casali P, Blay JY, Hohenberger P

Clin Cancer Res. 2012 Aug 15;18(16):4458-64

What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: surrogacy in question?

Bonnetain F, Bosset JF, Gerard JP, Calais G, Conroy T, Mineur L, Bouche O, Maingon P, Chapet O, Radosevic-Jelic L, Methy N, Collette L

Eur J Cancer. 2012 Aug;48(12):1781-90

Management of cutaneous adverse events induced by anti-EGFR (epidermal growth factor receptor): a French interdisciplinary therapeutic algorithm.

Reguiai Z, Bachet JB, Bachmeyer C, Peuvrel L, Beylot-Barry M, Bezier M, Boucher E, Chevelle C, Colin P, Guimbaud R, Mineur L, Richard MA, Artru P, Dufour P, Gornet JM, Samalin E, Bensadoun RJ, Ychou M, Andre T, Dreno B, Bouche O

Support Care Cancer. 2012 Jul;20(7):1395-404

Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial.

Peiffert D, Tournier-Rangeard L, Gérard JP, Lemanski C, François E, Giovannini M, Cvitkovic F, Mirabel X, Bouché O, Luporsi E, Conroy T, Montoto-Grillot C, Mornex F, Lusinchi A, Hannoun-Lévi JM, Seitz JF, Adenis A, Hennequin C, Denis B, Ducreux M

J. Clin. Oncol.. 2012 Jun;30(16):1941-8

Phase III randomized trial of definitive chemoradiotherapy (CRT) with FOLFOX or cisplatin and fluorouracil in esophageal cancer (EC): Final results of the PRODIGE 5/ACCORD 17 trial.

Galais MP, Raoul JL, Bouche O, Gourgou-Bourgade S, Douillard JY, Etienne PL, Boige V, Martel-Lafay I, Michel P, Llacer-Moscardo C, Berille J, Bedenne L, Adenis A

J. Clin. Oncol.. 2012 Jun;30(18_suppl):LBA4003

[News in management of colorectal cancer at JFHOD 2012 meeting].

Volet J, de Mestier L, Ehrhard F, Bouche O

Bull Cancer. 2012 Jun;99(6):703-13.

Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors.

Peuvrel L, Bachmeyer C, Reguiai Z, Bachet JB, Andre T, Bensadoun RJ, Bouche O, Ychou M, Dreno B

Support Care Cancer. 2012 May;20(5):909-21

Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.

Bennouna J, Borg C, Delord JP, Husseini F, Trillet-Lenoir V, Faroux R, Francois E, Ychou M, Goldwasser F, Bouche O, Senellart H, Kraemer S, Douillard JY

Clin Colorectal Cancer. 2012 Mar;11(1):38-44

Folliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: a systematic literature review.

Bachet JB, Peuvrel L, Bachmeyer C, Reguiai Z, Gourraud PA, Bouche O, Ychou M, Bensadoun RJ, Dreno B, Andre T

Oncologist. 2012;17(4):555-68

Is palliative laparoscopic hyperthermic intraperitoneal chemotherapy effective in patients with malignant hemorrhagic ascites?

de Mestier L, Volet J, Scaglia E, Msika S, Kianmanesh R, Bouché O

Case Rep Gastroenterol. 2012 Jan;6(1):166-70

Pancreas cancer-associated polymyositis of the legs regressing after cephalic duodenopancreatectomy: case report and review of the literature.

Amroun KL, De Mestier L, Deguelte-Lardiere S, Diebold MD, Bouche O, Kianmanesh R

JOP. 2012 Nov 10;13(6):674-6

A New Rapid and Sensitive LC-MS Assay for the Determination of Sorafenib in Plasma: Application to a Patient Undergoing Hemodialysis.

Bobin-Dubigeon C, Heurgue-Berlot A, Bouche O, Amiand MB, Le Guellec C, Bard JM

. 2011 Dec;25(12):705-10.

Management of gastrointestinal stromal tumours of limited size: proposals from a French panel of physicians.

Landi B, Bouché O, Guimbaud R, Aparicio T, Berger A, Bonvalot S, Buecher B, Blay JY, Boustière C, Coindre JM, Emile JF, Giovannini M, Lecomte T, Le Cesne A, Monges G, Napoléon B, Palazzo L, Chayvialle JA

Dig Liver Dis. 2011 Dec;43(12):935-9

Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial.

Ducreux M, Malka D, Mendiboure J, Etienne PL, Texereau P, Auby D, Rougier P, Gasmi M, Castaing M, Abbas M, Michel P, Gargot D, Azzedine A, Lombard-Bohas C, Geoffroy P, Denis B, Pignon JP, Bedenne L, Bouche O

Lancet Oncol. 2011 Oct;12(11):1032-44

Phase II trial of weekly alternating sequential BIBF 1120 and afatinib for advanced colorectal cancer.

Bouche O, Maindrault-Goebel F, Ducreux M, Lledo G, Andre T, Stopfer P, Amellal N, Merger M, De Gramont A

Anticancer Res. 2011 Jun;31(6):2271-81.

[Locally advanced unresectable pancreatic cancer: Induction chemoradiotherapy followed by maintenance gemcitabine versus gemcitabine alone: Definitive results of the 2000-2001 FFCD/SFRO phase III trial].

Barhoumi M, Mornex F, Bonnetain F, Rougier P, Mariette C, Bouche O, Bosset JF, Aparicio T, Mineur L, Azzedine A, Hammel P, Butel J, Stremsdoerfer N, Maingon P, Bedenne L, Chauffert B

Cancer Radiother. 2011 Jun;15(3):182-91

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, Bennouna J, Bachet JB, Khemissa-Akouz F, Pere-Verge D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M

N Engl J Med. 2011 May 12;364(19):1817-25.

Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.

Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G, Ducourtieux M, Bedenne L, Fabre JM, Saint-Aubert B, Geneve J, Lasser P, Rougier P

J Clin Oncol. 2011 May 1;29(13):1715-21

[HER2 and gastric cancer. Recommendations for clinical practice in 2011].

Penault-Llorca F, Chenard MP, Bouche O, Emile JF, Bibeau F, Metges JP, Andre T, Monges G

Ann Pathol. 2011 Apr;31(2):78-87

Development and validation of a new prognostic score of death for patients with hepatocellular carcinoma in palliative setting.

Tournoux-Facon C, Paoletti X, Barbare JC, Bouche O, Rougier P, Dahan L, Lombard-Bohas C, Faroux R, Raoul JL, Bedenne L, Bonnetain F

J Hepatol. 2011 Jan;54(1):108-14

Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas (MGA) treatment.

Samalin E, Afchain P, Thézenas S, Abbas F, Romano O, Guimbaud R, Bécouarn Y, Desseigne F, Edeline J, Mitry E, Bouché O, Adenis A, Aparicio T, Dorval E, Kramar A, Ychou M

Clin Res Hepatol Gastroenterol. 2011 Jan;35(1):48-54

[HER2 and gastric cancer: a novel therapeutic target for trastuzumab].

Bouché O, Penault-Llorca F

Bull Cancer. 2010 Dec;97(12):1429-40

Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer.

Perkins G, Lievre A, Ramacci C, Meatchi T, de Reynies A, Emile JF, Boige V, Tomasic G, Bachet JB, Bibeau F, Bouche O, Penault-Llorca F, Merlin JL, Laurent-Puig P

Int J Cancer. 2010 Sep 1;127(6):1321-31.

Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05.

Boige V, Mendiboure J, Pignon JP, Loriot MA, Castaing M, Barrois M, Malka D, Tregouet DA, Bouche O, Le Corre D, Miran I, Mulot C, Ducreux M, Beaune P, Laurent-Puig P

J Clin Oncol. 2010 May 20;28(15):2556-64

Phase II study of oral masitinib mesilate in imatinib-naive patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST).

Le Cesne A, Blay JY, Bui BN, Bouche O, Adenis A, Domont J, Cioffi A, Ray-Coquard I, Lassau N, Bonvalot S, Moussy A, Kinet JP, Hermine O

Eur J Cancer. 2010 May;46(8):1344-51

Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2.

Gerard JP, Azria D, Gourgou-Bourgade S, Martel-Laffay I, Hennequin C, Etienne PL, Vendrely V, Francois E, de La Roche G, Bouche O, Mirabel X, Denis B, Mineur L, Berdah JF, Mahe MA, Becouarn Y, Dupuis O, Lledo G, Montoto-Grillot C, Conroy T

J Clin Oncol. 2010 Apr 1;28(10):1638-44

Surrogate end points for overall survival and local control in neoadjuvant rectal cancer trials: statistical evaluation based on the FFCD 9203 trial.

Methy N, Bedenne L, Conroy T, Bouche O, Chapet O, Ducreux M, Gerard JP, Bonnetain F

Ann Oncol. 2010 Mar;21(3):518-24

The role of anti-epidermal growth factor receptor monoclonal antibody monotherapy in the treatment of metastatic colorectal cancer.

Bouche O, Beretta GD, Alfonso PG, Geissler M

Cancer Treat Rev. 2010 Feb;36 Suppl 1:S1-10.

[Gastrointestinal stromal tumors (GIST)

Landi B, Bouche O, Guimbaud R, Chayvialle JA

Gastroenterol Clin Biol. 2010 Feb;34(2):120-33

[Prerequisites to the administration and prevention of adverse effects of chemotherapy in colorectal cancer].

Bouché O, Scaglia E, Lagarde S

Bull Cancer. 2010 Feb;97(2):265-80

Experience of gemcitabine plus oxaliplatin chemotherapy in patients with advanced biliary tract carcinoma.

Hollebecque A, Bouche O, Romano O, Scaglia E, Cattan S, Zerbib P, Heurgue A, Lagarde S, Mariette C, Triboulet JP, Pruvot FR, Hebbar M

Chemotherapy. 2010;56(3):234-8

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, Rougier P, Lievre A, Landi B, Boige V, Ducreux M, Ychou M, Bibeau F, Bouche O, Reid J, Stone S, Penault-Llorca F

J Clin Oncol. 2009 Dec 10;27(35):5924-30

Identification of Raman spectroscopic markers for the characterization of normal and adenocarcinomatous colonic tissues.

Beljebbar A, Bouche O, Diebold MD, Guillou PJ, Palot JP, Eudes D, Manfait M

Crit Rev Oncol Hematol. 2009 Dec;72(3):255-64

Imaging techniques to evaluate the response to treatment in oncology: current standards and perspectives.

Marcus CD, Ladam-Marcus V, Cucu C, Bouche O, Lucas L, Hoeffel C

Crit Rev Oncol Hematol. 2009 Dec;72(3):217-38

Vascular and renal effects of anti-angiogenic drugs: recommendations for French practice. (The Company of Nephrology, American Society of Hypertension, National Educational Association of Teachers of Therapeutics and Francophone Federation of Digestive Ca

Halimi JM, Azizi M, Bobrie G, Bouche O, Deray G, des Guetz G, Lecomte T, Levy B, Mourad JJ, Nochy D, Oudard S, Rieu P, Sahali D

Oncologie. 2009 Sep;11(9-10):476-89

Postoperative imaging after colorectal surgery

Hoeffel C, Marcus C, Arrive L, Bouche O, Tubiana JM

J Radiol. 2009 Jul-Aug;90(7-8 Pt 2):954-68.

Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study.

Barbare JC, Bouché O, Bonnetain F, Dahan L, Lombard-Bohas C, Faroux R, Raoul JL, Cattan S, Lemoine A, Blanc JF, Bronowicki JP, Zarski JP, Cazorla S, Gargot D, Thevenot T, Diaz E, Bastie A, Aparicio T, Bedenne L

Eur. J. Cancer. 2009 Jul;45(10):1788-97

Increased risk of colonic neoplasia in patients with sporadic duodenal adenoma.

Lagarde S, Dauphin M, Delmas C, Vitry F, Bouche O, Thiefin G, Diebold MD, Cadiot G

Gastroenterol Clin Biol. 2009 May;33(5):441-5

A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802).

Ychou M, Raoul JL, Douillard JY, Gourgou-Bourgade S, Bugat R, Mineur L, Viret F, Becouarn Y, Bouche O, Gamelin E, Ducreux M, Conroy T, Seitz JF, Bedenne L, Kramar A

Ann Oncol. 2009 Apr;20(4):674-80

[Targeted biotherapies in digestive oncology: management of adverse effects]

Bouche O, Scaglia E, Reguiai Z, Singha V, Brixi-Benmansour H, Lagarde S

Gastroenterol Clin Biol. 2009 Apr;33(4):306-22

Optical diagnosis of peritoneal metastases by infrared microscopic imaging.

Untereiner V, Piot O, Diebold MD, Bouche O, Scaglia E, Manfait M

Anal Bioanal Chem. 2009 Mar;393(6-7):1619-27

Pelvic MRI at 3.0 Tesla

Leautaud A, Marcus C, Ben Salem D, Bouche O, Graesslin O, Hoeffel C

J Radiol. 2009 Mar;90(3 Pt 1):277-86.

Advances in radiological imaging of gastrointestinal tumors.

Hoeffel C, Mule S, Romaniuk B, Ladam-Marcus V, Bouche O, Marcus C

Crit Rev Oncol Hematol. 2009 Feb;69(2):153-67

Patient-reported outcomes as a component of the primary endpoint in a double-blind, placebo-controlled trial in advanced pancreatic cancer.

Eckhardt SG, De Porre P, Smith D, Maurel J, Steward WP, Bouche O, van de Velde H, Michiels B, Bugat R

J Pain Symptom Manage. 2009 Feb;37(2):135-43

Vascular and renal effects of anti-angiogenic medicines: French recommendations for practice (Nephrology Society, French Arterial Hypertension Society, National Pedagogical Association for therapeutic teaching and Francophone Federation of digestive cance

Halimi JM, Azizi M, Bobrie G, Bouche O, Deray G, des Guetz G, Lecomte T, Levy B, Mourad JJ, Nochy D, Oudard S, Rieu P, Sahali D

Sang Thromb Vaiss. 2009;21(3):151-66

[Vascular and renal effects of anti-angiogenic therapy]

Halimi JM, Azizi M, Bobrie G, Bouche O, Deray G, des Guetz G, Lecomte T, Levy B, Mourad JJ, Nochy D, Oudard S, Rieu P, Sahali D

Nephrol Ther. 2008 Dec;4(7):602-15

Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials.

Mitry E, Fields AL, Bleiberg H, Labianca R, Portier G, Tu D, Nitti D, Torri V, Elias D, O'Callaghan C, Langer B, Martignoni G, Bouche O, Lazorthes F, Van Cutsem E, Bedenne L, Moore MJ, Rougier P

J Clin Oncol. 2008 Oct 20;26(30):4906-11

Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2

Chauffert B, Mornex F, Bonnetain F, Rougier P, Mariette C, Bouche O, Bosset JF, Aparicio T, Mineur L, Azzedine A, Hammel P, Butel J, Stremsdoerfer N, Maingon P, Bedenne L

Ann Oncol. 2008 Sep;19(9):1592-9

Quality of life as a prognostic factor of overall survival in patients with advanced hepatocellular carcinoma: results from two French clinical trials.

Bonnetain F, Paoletti X, Collette S, Doffoel M, Bouche O, Raoul JL, Rougier P, Masskouri F, Barbare JC, Bedenne L

Qual Life Res. 2008 Aug;17(6):831-43

Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials.

Collette S, Bonnetain F, Paoletti X, Doffoel M, Bouche O, Raoul JL, Rougier P, Masskouri F, Bedenne L, Barbare JC

Ann Oncol. 2008 Jun;19(6):1117-26

Endoscopic ultrasonography is an independent predictive factor of prognosis in locally advanced esophageal cancer. Results from the randomized FFCD 9102 study from the Federation Francophone de Cancerologie Digestive.

Burtin P, Bouche O, Giovannini M, Pelletier M, Conroy T, Ruget O, Arsene D, Milan C, Bedenne L

Gastroenterol Clin Biol. 2008 Mar;32(3):213-20

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouche O, Landi B, Louvet C, Andre T, Bibeau F, Diebold MD, Rougier P, Ducreux M, Tomasic G, Emile JF, Penault-Llorca F, Laurent-Puig P

J Clin Oncol. 2008 Jan 20;26(3):374-9.

Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial.

Boige V, Raoul JL, Pignon JP, Bouche O, Blanc JF, Dahan L, Jouve JL, Dupouy N, Ducreux M

Br J Cancer. 2007 Oct 8;97(7):862-7

Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1.

Andre T, Quinaux E, Louvet C, Colin P, Gamelin E, Bouche O, Achille E, Piedbois P, Tubiana-Mathieu N, Boutan-Laroze A, Flesch M, Lledo G, Raoul Y, Debrix I, Buyse M, de Gramont A

J Clin Oncol. 2007 Aug 20;25(24):3732-8.

Outcome after surgical treatment of gastrointestinal stromal tumors

Weber AG, Jovenin N, Lubrano D, Journu J, Yaziji N, Bouche O, Diebold MD, Delattre JF

Gastroenterol Clin Biol. 2007 Jun-Jul;31(6-7):579-84.

Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102.

Bedenne L, Michel P, Bouché O, Milan C, Mariette C, Conroy T, Pezet D, Roullet B, Seitz JF, Herr JP, Paillot B, Arveux P, Bonnetain F, Binquet C

J. Clin. Oncol.. 2007 Apr;25(10):1160-8

Assessment of baseline clinical predictive factors of response to cetuximab-irinotecan in patients with irinotecan-refractory metastatic colorectal cancer.

Hebbar M, Di Fiore F, Conroy T, Giraud C, Gasnault L, Fournier C, Pereira R, Bouche O, Fournier P, Deligny N, Joly JP, Maes P, Rad E, Michel P, Adenis A

Oncology. 2007;73(3-4):185-91

Beneficial influence of microsatellite instability on gelatinase-tissue inhibitors of metalloproteinase balance in colorectal cancer

Thiefin G, Dupont A, Guillou PJ, Vitry F, Bouche O, Yaziji N, Lagarde S, Maquart FX, Palot JP, Hornebeck W, Diebold MD

Anticancer Res. 2007 Jan-Feb;27(1B):583-8.

Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial.

Portier G, Elias D, Bouche O, Rougier P, Bosset JF, Saric J, Belghiti J, Piedbois P, Guimbaud R, Nordlinger B, Bugat R, Lazorthes F, Bedenne L

J Clin Oncol. 2006 Nov 1;24(31):4976-82.

Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.

Gerard JP, Conroy T, Bonnetain F, Bouche O, Chapet O, Closon-Dejardin MT, Untereiner M, Leduc B, Francois E, Maurel J, Seitz JF, Buecher B, Mackiewicz R, Ducreux M, Bedenne L

J Clin Oncol. 2006 Oct 1;24(28):4620-5.

[What changes were made in the National Thesaurus of Gastrointestinal Cancer in 2005?].

Legoux JL, Bedenne L, Seitz JF, Pezet D, Rougier P, Bouche O, Barbare JC, Andre T, Malka D, Cadiot G, Ruskone-Foumestraux A, Landi B, Peiffert D, Ducreux M, Louvet C, Dorval E

Gastroenterol Clin Biol. 2006 Oct;30(10):1191-5.

Gastrointestinal stromal tumors (GIST).

Landi B, Bouche O, Blay JY

Gastroenterol Clin Biol. 2006 Sep;30 Spec No 2:2S98-2S101.

Gastrointestinal stromal tumors (GIST).

Landi B, Bouche O, Blay JY

Gastroenterol Clin Biol. 2006 Sep;30:S98-101.

Metastatic colorectal cancer.

Bouche O, Conroy T, Michel P, Penna C, Tournigand C

Gastroenterol Clin Biol. 2006 Sep;30:S30-42.

Metastatic colorectal cancer.

Bouche O, Conroy T, Michel P, Penna C, Tournigand C

Gastroenterol Clin Biol. 2006 Sep;30 Spec No 2:2S30-2S42.

Safety of cisplatin combined with continuous 5-FU versus bolus 5-FU and leucovorin, in metastatic gastrointestinal cancer (FFCD 9404 randomised trial).

Duffour J, Bouche O, Rougier P, Milan C, Bedenne L, Seitz JF, Buecher B, Legoux JL, Ducreux M, Vetter D, Raoul JL, Francois E, Ychou M

Anticancer Res. 2006 Sep-Oct;26(5B):3877-83.

[Recommendations for the management of gastro-intestinal stromal tumors].

Le Cesne A, Landi B, Bonvalot S, Monges G, Ray-Coquard I, Duffaud F, Bui Nguyen B, Bugat R, Chayvialle JA, Rougier P, Bouche O, Bonichon F, Lassau N, Vanel D, Nordlinger B, Stoeckle E, Meeus P, Coindre JM, Scoazec JY, Emile JF, Ranchere D, Blay JY

Ann Pathol. 2006 Jun;26(3):231-4.

A comparative longitudinal quality of life study using the Spitzer quality of life index in a randomized multicenter phase III trial (FFCD 9102): chemoradiation followed by surgery compared with chemoradiation alone in locally advanced squamous resectable

Bonnetain F, Bouché O, Michel P, Mariette C, Conroy T, Pezet D, Roullet B, Seitz JF, Paillot B, Arveux P, Milan C, Bedenne L

Ann. Oncol.. 2006 May;17(5):827-34

[Flushing revealing the recurrence of a rectal gastrointestinal stromal tumour. Efficacy of imatinib].

Bouche O, Lagarde S, Guillou PJ, Ramaholimihaso F, Lubrano D, Diebold MD, Delattre JF, Nguyen TD, Cadiot G, Thiefin G

Gastroenterol Clin Biol. 2006 Apr;30(4):636-7.

Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma. Results of a phase II trial.

Mitry E, Ducreux M, Ould-Kaci M, Boige V, Seitz JF, Bugat R, Breau JL, Bouche O, Etienne PL, Tigaud JM, Morvan F, Cvitkovic E, Rougier P

Gastroenterol Clin Biol. 2006 Mar;30(3):357-63.

[Recommendations for clinical practice: management of stomach adenocarcinoma].

Ychou M, Bouche O, Marchal F, Merrouche Y, Gory-Delabaere G

Bull Cancer. 2006 Feb 1;93(2):192-6.

[Recommendations for clinical practice: management with first-line palliative chemotherapy for patients with metastatic colorectal cancer].

Conroy T, Adeni A, Bouché O, Merrouche Y, Mitry E, Gory-Delabaere G, ,,,,,,,,,

Bull Cancer. 2006 Feb;93(2):197-200

Cost-effectiveness analysis of first-line chemotherapies in metastatic colorectal cancer. Results of the Federation Francophone de Cancerologie Digestive (FFCD) 9601 randomized trial.

Borget I, Auperin A, Pignon JP, Abbas M, Bouche O, Mousseau M, Raoul JL, Bedenne L, Cassan P, Clavero-Fabri MC, Stremsdoerfer N, Nasca S, Queuniet AM, Ducreux M

Oncology. 2006;71(1-2):40-8

Randomised trial comparing three different schedules of infusional 5FU and raltitrexed alone as first-line therapy in metastatic colorectal cancer. Final results of the Federation Francophone de Cancerologie Digestive (FFCD) 9601 trial.

Ducreux M, Bouche O, Pignon JP, Mousseau M, Raoul JL, Cassan P, Leduc B, Berger C, Dunant A, Fournet J, Bedenne L

Oncology. 2006;70(3):222-30

[Metastasis of pancreatic cancer in an old cholecystectomy scar].

Moncoucy X, Bouche O, Delattre JF, Diebold MD, Cadiot G, Thiefin G

Gastroenterol Clin Biol. 2005 Nov;29(11):1182-3.

Trichomegaly of the eyelashes following treatment with cetuximab.

Bouche O, Brixi-Benmansour H, Bertin A, Perceau G, Lagarde S

Ann Oncol. 2005 Oct;16(10):1711-2

[Recommendations for the management of GIST patients].

Blay JY, Landi B, Bonvalot S, Monges G, Ray-Coquard I, Duffaud F, Bui NB, Bugat R, Chayvialle JA, Rougier P, Bouche O, Bonichon F, Lassau N, Vanel D, Nordlinger B, Stoeckle E, Meeus P, Coindre JM, Scoazec JY, Emile JF, Ranchere D, Le Cesne A

Bull Cancer. 2005 Oct 1;92(10):907-18.

Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801).

Bouche O, Ychou M, Burtin P, Bedenne L, Ducreux M, Lebreton G, Baulieux J, Nordlinger B, Martin C, Seitz JF, Tigaud JM, Echinard E, Stremsdoerfer N, Milan C, Rougier P

Ann Oncol. 2005 Sep;16(9):1488-97

Small bowel adenocarcinoma in patients with Crohn's disease compared with small bowel adenocarcinoma de novo.

Palascak-Juif V, Bouvier AM, Cosnes J, Flourie B, Bouche O, Cadiot G, Lemann M, Bonaz B, Denet C, Marteau P, Gambiez L, Beaugerie L, Faivre J, Carbonnel F

Inflamm Bowel Dis. 2005 Sep;11(9):828-32.

[Fistula between Wirsung and psoas muscle].

Weber AG, Perez T, Bouche O, Journu J, Poilblanc M, Levy-Chazal N, Avisse C, Lubrano D

Ann Chir. 2005 Sep;130(8):487-90.

Adjuvant regional chemotherapy and systemic chemotherapy versus systemic chemotherapy alone in patients with stage II-III colorectal cancer: a multicentre randomised controlled phase III trial.

Nordlinger B, Rougier P, Arnaud JP, Debois M, Wils J, Ollier JC, Grobost O, Lasser P, Wals J, Lacourt J, Seitz JF, Guimares dos Santos J, Bleiberg H, Mackiewickz R, Conroy T, Bouché O, Morin T, Baila L, van Cutsem E, Bedenne L

Lancet Oncol.. 2005 Jul;6(7):459-68

Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma.

Barbare JC, Bouche O, Bonnetain F, Raoul JL, Rougier P, Abergel A, Boige V, Denis B, Blanchi A, Pariente A, Milan C, Bedenne L

J Clin Oncol. 2005 Jul 1;23(19):4338-46.

[Poorly differentiated endocrine carcinoma and adenocarcinoma on Barrett's esophagus].

Heurgue A, Bouche O, Higuero T, Lagarde S, Diebold MD, Thiefin G, Cadiot G

Gastroenterol Clin Biol. 2005 May;29(5):613-4.

[Targeted biotherapies in digestive oncology: a new era in therapeutic management?].

Bouche O

Gastroenterol Clin Biol. 2005 May;29(5):495-500.

Risk factors and long-term course of thyroid dysfunction during antiviral treatments in 221 patients with chronic hepatitis C.

Moncoucy X, Leymarie F, Delemer B, Levy S, Bernard-Chabert B, Bouche O, Jolly D, Diebold MD, Cadiot G, Thiefin G

Gastroenterol Clin Biol. 2005 Apr;29(4):339-45.

[Clinical Practice Guidelines 2004. Standards, Options and Recommendations for the management of patient with adenocarcinoma of the stomach: radiotherapy (therapeutic evaluation)].

Ychou M, Gory-Delabaere G, Blanc P, Bosquet L, Duffour J, Giovannini M, Guillemin F, Lemanski C, Marchal F, Masson B, Merrouche Y, Monges G, Adenis A, Bosset JF, Bouche O, Conroy T, Pezet D, Triboulet JP

Bull Cancer. 2005 Apr;92(4):381-409.

[Helicobacter heilmannii-associated low-grade gastric MALT lymphoma: a new case of complete remission after eradication].

Thomas-Marques L, Yaziji N, Bouché O, Diebold MD, Cadiot G, Thiéfin G

Gastroenterol. Clin. Biol.. 2005 Apr;29(4):476-7

[Small bowel adenocarcinoma revealing Crohn's disease].

Bensoussan M, Bouche O, Fremond L, Yaziji-Cucherousset N, Diebold MD, Palot JP, Thiefin G, Cadiot G

Gastroenterol Clin Biol. 2005 Feb;29(2):210-1.

Postoperative chemoradiotherapy after surgical resection of gastric adenocarcinoma: can LV5FU2 reduce the toxic effects of the MacDonald regimen? A report on 23 patients.

Dahan L, Atlan D, Bouche O, Mitry E, Ries P, Artru P, Richard K, Lledo G, Nguyen T, Rougier P, Seitz JF

Gastroenterol Clin Biol. 2005 Jan;29(1):11-5.

[How can the prognosis of gastric cancer be improved in France?].

Bouche O

Gastroenterol Clin Biol. 2005 Jan;29(1):7-10.

[Stomach cancer].

Bouche O, Lagarde S

Rev Prat. 2005 Jan 31;55(2):123-30.

Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie

Bouche O, Raoul JL, Bonnetain F, Giovannini M, Etienne PL, Lledo G, Arsene D, Paitel JF, Guerin-Meyer V, Mitry E, Buecher B, Kaminsky MC, Seitz JF, Rougier P, Bedenne L, Milan C

J Clin Oncol. 2004 Nov 1;22(21):4319-28.

[Clinical practice guideline: 2003 update of Standards, Options et Recommendations for first line palliative chemotherapy in patients with metastatic colorectal cancer (summary report)].

Conroy T, Gory-Delabaere G, Adenis A, Bosquet L, Bouché O, Louvet C, Mitry E, Bécouarn Y, Bosset JF, Ducreux M, Etienne PL, Merrouche Y, Monges G, Rougier P, ,,,,,,,

Bull Cancer. 2004 Oct;91(10):759-68

[Clinical practice guidelines: 2004 Standards, Options and Recommendations for the management of patient with adenocarcinoma of the stomach--radiotherapy].

Ychou M, Gory-Delabaere G, Blanc P, Bosquet L, Duffour J, Giovannini M, Guillemin F, Lemanski C, Marchal F, Masson B, Merrouche Y, Monges G, Adenis A, Bosset JF, Bouché O, Conroy T, Pezet D, Triboulet JP, ,,

Cancer Radiother. 2004 Oct;8(5):322-35

Colonic flat neoplasia: frequency and concordance between endoscopic appearance and histological diagnosis in a French prospective series.

Diebold MD, Samalin E, Merle C, Bouché O, Higuero T, Jolly D, Ramaholimihaso F, Renard P, Yaziji N, Thiéfin G, Cadiot G

Am. J. Gastroenterol.. 2004 Sep;99(9):1795-800

Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients.

Ducreux M, Mitry E, Ould-Kaci M, Boige V, Seitz JF, Bugat R, Breau JL, Bouché O, Etienne PL, Tigaud JM, Morvan F, Cvitkovic E, Rougier P

Ann. Oncol.. 2004 Mar;15(3):467-73

Longitudinal quality of life (QoL) study in a randomized phase II trial (FFCD 9803) assessing LV5FU2, LV5FU2-cisplatin or LV5FU2-irinotecan in patients (pts) with metastatic gastric adenocarcinoma (MGA).

Bonnetain F, Bouche O, Raoul J, Giovannini M, Etienne P, Bedenne L, Seitz J, Lledo G, Conroy T, Arveux P

Proc Am Soc Clin Oncol 23, 2004.

Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial.

Andre T, Colin P, Louvet C, Gamelin E, Bouche O, Achille E, Colbert N, Boaziz C, Piedbois P, Tubiana-Mathieu N, Boutan-Laroze A, Flesch M, Buyse M, de Gramont A

J. Clin. Oncol.. 2003 Aug;21(15):2896-903

Cancers colorectaux au stade superficial : des diff

DIMNET-GRUYER A, GRANIER E, COUDOL P, YAZIJI N, PALOT JP, BOUCHE O, CADIOT G, THIEFIN G, LAURENT-PUIG P, DIEBOLD MD

Bull Cancer 2003 ; 90 (6)

Definitive results of a comparative longitudinal quality of life study using the Spitzer index in the randomized multicentric phase III trial FFCD 9102 (surgery vs radiochemotherapy in patients with locally advanced esophageal cancer).

Bonnetain F, Bedenne L, Michel P, Bouche O, Triboulet JP, Conroy T, Pezet D, Roullet B, Milan C, Arveux P, FFCD

Proc Am Soc Clin Oncol 22: page 250, 2003 (abstr 1002)

Randomized adjuvant study comparing two schemes of 5-fluorouracil and leucovorin in stage B2 and C colon adenocarcinoma: study design and preliminary safety results. Groupe d'Etude et de Recherche Clinique en Oncologie Radiotherapies.

André T, Colin P, Louvet C, Gamelin E, Bouche O, Achille E, Colbert N, Boaziz C, Piedbois P, Tubiana-Mathieu N, Boutan-Laroze A, Flesch M, Billiau V, Buyse M, Gramont A,

Semin. Oncol.. 2001 Feb;28(1 Suppl 1):35-40

Bleeding reflux esophagitis: a prospective 1-year study in a university hospital.

Costa ND, Cadiot G, Merle C, Jolly D, Bouche O, Thiéfin G, Zeitoun P

Am. J. Gastroenterol.. 2001 Jan;96(1):47-51

Morphological and clinical characteristics of 41 cases of flat colorectal cancers (pT1 stage)

SOUSSI F, DIEBOLD MD, DIMNET A, YAZIJI N, PALOT JP, BOUCHE O, ISSAH S, CADIOT G, THIEFIN G

Gastroenterology 2001 ; 120 (5) : A258

Pr BOUCHE Olivier

Fiche personne

Coordonnées

Territoire

Statut

Affiliation

Équipes/plateformes

Projets

Publications